



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> :  C12N 15/53, 9/02, 1/21, 15/01, C12P 7/02 // (C12N 9/02, C12R 1:40) (C12N 9/02, C12R 1:11) (C12N 1/21, C12R 1:19)	A2	(11) International Publication Number: <b>WO 00/31273</b>  (43) International Publication Date: 2 June 2000 (02.06.00)
(21) International Application Number: PCT/GB99/03873		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 19 November 1999 (19.11.99)		
(30) Priority Data: 9825421.2 19 November 1998 (19.11.98) GB		
(71) Applicant (for all designated States except US): ISIS INNOVATION LIMITED [GB/GB]; Ewert House, Ewert Place, Summertown, Oxford OX2 7BZ (GB).		
(72) Inventors; and		
(75) Inventors/Applicants (for US only): WONG, Luet, Lok [GB/GB]; University of Oxford, Dept. of Chemistry, South Parks Road, Oxford OX1 3QR (GB). BELL, Stephen, Graham [GB/GB]; University of Oxford, Dept. of Chemistry, South Parks Road, Oxford OX1 3QR (GB). CARMICHAEL, Angus, Bishop [GB/GB]; University of Oxford, Dept. of Chemistry, South Parks Road, Oxford OX1 3QR (GB).		
(74) Agent: ELLIS-JONES, Patrick, George, Armine; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5LX (GB).		

(54) Title: PROCESS FOR OXIDISING TERPENES

## (57) Abstract

A process for oxidising a substrate which is an acyclic or cyclic terpene, or a cycloalkene; or a substituted derivative thereof, which process comprises oxidising said compound with a mutant haem-containing enzyme, the mutant comprising the substitution of an amino acid in the active site by an amino acid with a less polar side-chain. The enzyme is typically P450<sub>cam</sub> or P450<sub>BM-3</sub>. Cells and libraries of cells in which the process can be carried out or which can be used to select advantageous mutant enzymes are also provided.

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

PROCESS FOR OXIDISING TERPENES

The invention relates to a process for enzymatically oxidising terpenes and cycloalkenes.

Terpenoid compounds are widespread in biological systems and constitute one of the largest class of natural products. They are major constituents of essential oils, some of which are of considerable value in the flavour and perfume industries. Many terpenoids are also biologically active. Some are anti-bacterial and anti-fungal agents and thus are of great interest to the pharmaceutical industry. Indeed, terpenoids are some of the highest added value chemicals.

The terpenoids of commercial interest are not normally the terpenes themselves, but rather derivatives which commonly require stereoselective functionalisation at allylic as well as non-activated carbon-hydrogen bonds of the parent terpene. This type of chemical transformation is one of the most difficult reaction to carry out by conventional methods of chemical synthesis - the highly reactive chemical oxidising agents required are non-selective and typically they will preferentially attack more activated carbon-hydrogen bonds and reactive functional groups such as olefinic double bonds commonly present in terpenes.

The present invention concerns the enzymatic oxidation of terpenes and cycloalkenes. This technique enables the synthesis of hydroxylated terpenes (and cycloalkenes), often in a single step, and provided that the match between substrate and enzyme is correct, the oxidation reaction can be highly chemoselective (attack at a particular functional group such as a non-activated C-H bond rather than some other reactive functional group) and stereoselective. The fine tuning and alterations of substrate specificity and selectivity of substrate oxidation are very difficult to achieve for

-2-

conventional reagents.

The present invention provides a process for oxidising a substrate which is an acyclic or cyclic terpene or a cycloalkene, or a substituted derivative thereof, which process comprises oxidising said compound with a mutant haem-containing enzyme, the mutant comprising the substitution of an amino acid in the active site by an amino acid with a less polar side-chain.

Although the terpenes used in the present invention will generally have the formula  $(C_5H_8)_n$  where n is 2 or more, especially 2, 3 or 4, it is to be understood that the term "terpene" extends to compounds which are strictly referred to as "terpenoid", involving the loss or shift of a fragment, generally a methyl group. Thus, for example, sesquiterpenes (where n is 3) which can be used in the present invention may contain only, say, 14, rather than 15, carbon atoms. Generally the terpene is one which can be built up from isoprene units. The terpene may be cyclic or acyclic.

The monoterpenes (where n is 2) will generally have 10 carbon atoms, typically with 1 to 3 double bonds, especially 1 or 2 ring double bonds, and typically with 0 to 2 rings. It is possible for one of the rings to be formed as a bridge containing, typically 0 or 1 carbon atoms. In other words, it can be formed by a direct link between 2 carbon atoms of an existing ring or with an intermediate methylene group. If the terpene is acyclic it will generally contain at least 2 double bonds and generally 3.

The sesquiterpenes will normally contain 14 or 15 carbon atoms, typically with 0 to 2 double bonds and typically 1 to 3 rings, with the possibility of fused rings and/or bridged rings.

The rings which may be present in the terpenes will

-3-

typically have from 3 to 9 carbon atoms, more especially 5 or 6 carbon atoms. Thus, in particular, the terpenes will contain a cyclohexane, or cyclohexadiene ring.

The terpenes will generally contain a total of 3 or 5 4 exocyclic methyl or methylene groups, for example 2 methyl groups and 1 methylene group or 3 methyl groups for a monoterpane, and 3 methyl groups and 1 methylene group or 4 methyl groups for a sesquiterpene.

The monoterpane is typically a limonene, pinene, terpinene, sabinene, thujene, mercene, ocimene, nerol or geraniol, for example as shown in Table 1.

The sesquiterpene is generally formed by a head-to-tail arrangement of three isoprene units. The sesquiterpene is typically an aromadendrene, caryophyllene, longifolene, valencene, isobazzanene, silphinene, ishwarane, isopatchchoul-3-ene, or isosesquicarene, for example as shown in Table 2.

The diterpene (where n is 4) is typically casbene, retinal, abietic acid or a gibberellin.

The cycloalkene generally comprises up to 9 ring members, e.g. it is a 5, 6, 7, 8, 9 or more membered ring. The cycloalkene is typically a cyclohexene.

Substituted derivatives of any of the terpenes or cycloalkenes mentioned above may also be used. Typically 1, 2, 3 or more substituents are present. Any combination of the following substituents may be present. The substituent is typically a halogen atom or an alkyl or alkenyl group, which generally has 1 to 6 carbons, the substituent optionally being substituted with one or more halogens. It is generally not phenylcyclohexene. Indeed the presence of aromatic, such as phenyl, rings is generally avoided for all the substrates used in the invention.

The substituent typically has the formula  $C_nH_kX_m$ , wherein X is the halogen, n is 1, 2, 3 or more, m is 1,

-4-

2, 3, 4 or more and k is an integer which has an appropriate value so that the valencies of the substituent  $C_nH_kX_m$  are satisfied. For an alkyl substituent  $k+m = 2n+1$ . Typically k is 1, 2, 3, 4 or 5 more, or may be 0, i.e. the substituent is a perhaloalkyl group. The halogen is typically fluorine, chlorine or bromine.

The substituent may also comprise 1, 2 or more oxygen atoms and for example may be an alcohol, aldehyde, 10 ketone or epoxide group.

The oxidation causes the formation of a C-O bond in the compound, generally as the hydroxide from the oxidation of a carbon-hydrogen bond, but an epoxide may be formed from the oxidation of a C=C bond. The 15 oxidation may thus introduce a hydroxy, aldehyde, ketone or epoxide group. Alternatively the oxidation may cause the further oxidation of an oxygen containing group, such as converting a hydroxy group into an aldehyde or ketone group. 1, 2 or more carbon atoms may be attacked in the 20 same substrate molecule.

The oxidation typically gives rise to 1, 2 or more oxidation products. These different products may result from different carbon atoms being attacked and/or from different degrees of oxidation occurring at a given 25 carbon atom.

The oxidation may occur on either a ring carbon atom or a substituent carbon atom or both. At least the initial oxidation will involve attack of a C-H bond which may be activated or non-activated or attack at a carbon- 30 carbon double bond (typically giving an epoxide).

Generally an activated C-H bond is where the carbon atom is in a benzylic or allyl position. Aromatic rings and olefinic double bonds activate C-H bonds to attack by stabilising the radical intermediate or any build-up of 35 charge generated during the reaction pathway. The

-5-

carbon of the C-H bond may be a primary, secondary or tertiary carbon.

The oxidation typically preserves stereoisomerism. Thus when the substrate consists of a single stereoisomer the product typically consists of a single corresponding stereoisomer, or can contain a preponderance of the corresponding stereoisomer.

The enzyme used in the process is generally a P450 enzyme, typically of eukaryotic or prokaryotic origin.

10 The enzyme is generally of bacterial, fungal, yeast, plant or animal origin, and thus may be from a bacterium of the genus *Pseudomonas*. The enzyme is typically a monooxygenase. The non-mutant form of the enzyme may or may not be able to oxidize terpenes and/or cycloalkenes.

15 The mutations discussed herein are generally introduced into the enzyme by using methods known in the art, such as site directed mutagenesis of the enzyme, PCR and gene shuffling methods or by the use of multiple mutagenic oligonucleotides in cycles of site-directed mutagenesis. Thus the mutations may be introduced in a directed or random manner. The mutagenesis method thus produces one or more polynucleotides encoding one or more different mutants. Typically a library of mutant oligonucleotides is produced which can be used to produce 20 a library of mutant enzymes.

An amino acid 'in the active site' is one which lines or defines the site in which the substrate is bound during catalysis or one which lines or defines a site through which the substrate must pass before reaching the 25 catalytic site. Therefore such an amino acid typically interacts with the substrate during entry to the catalytic site or during catalysis. Such an interaction typically occurs through an electrostatic interaction (between charged or polar groups), hydrophobic 30 interaction, hydrogen bonding or van der Waals forces.

-6-

The amino acids in the active site can be identified by routine methods to those skilled in the art. These methods include labelling studies in which the enzyme is allowed to bind a substrate which modifies ('labels') amino acids which contact the substrate. Alternatively the crystal structure of the enzyme with bound substrate can be obtained in order to deduce the amino acids in the active site.

The enzyme may have 1, 2, 3, 4, 5 to 10, 10 to 20 or more other mutations, such as substitutions, insertions or deletions. The other mutations may be in the active site or outside the active site. Typically the mutations are in the 'second sphere' residues which affect or contact the position or orientation of one or more of the amino acids in the active site. The insertion is typically at the N and/or C terminal and thus the enzyme may be part of a fusion protein. The deletion typically comprises the deletion of amino acids which are not involved in catalysis, such as those outside the active site (thus the enzyme is a mutated fragment of a naturally occurring enzyme). The enzyme may thus comprise only those amino acids which are required for oxidation activity.

The other mutation in the active site typically alters the position and/or conformation of the substrate when it is bound in the active site. The mutation may make the site on the substrate which is to be oxidized more accessible to the haem group. Thus the mutation may be a substitution to an amino acid which has a smaller or larger, or more or less polar, side chain.

The other mutations typically increase the stability of the protein, or make it easier to purify the protein. They typically prevent the dimerisation of the protein, typically by removing cysteine residues from the protein (e.g. by substitution of cysteine at position 334

-7-

of P450<sub>cam</sub>, or at an equivalent position in a homologue, preferably to alanine). They typically allow the protein to be prepared in soluble form, for example by the introduction of deletions or a poly-histidine tag, or by mutation of the N-terminal membrane anchoring sequence. The mutations typically inhibit protein oligomerisation, such as oligomerisation arising from contacts between hydrophobic patches on protein surfaces.

Thus the mutant enzyme is typically at least 70% homologous to a naturally occurring haem-containing enzyme on the basis of amino acid identity.

Any of the homologous proteins (i.e. described as being homologous to another protein) mentioned herein are typically at least 70% homologous to the relevant protein or at least 80 or 90% and more preferably at least 95%, 97% or 99% homologous thereto over at least 20, preferably at least 30, for instance at least 40, 60 or 100 or more contiguous amino acids. The contiguous amino acids may include the active site. This homology may alternatively be measured not over contiguous amino acids but over only the amino acids in the active site.

Homology can be measured using known methods. For example the UWGCG Package provides the BESTFIT program which can be used to calculate homology (for example used on its default settings) (Devereux et al (1984) *Nucleic Acids Research* 12, p387-395). The PILEUP and BLAST algorithms can be used to calculate homology or line up sequences (typically on their default settings), for example as described in Altschul S. F. (1993) *J Mol Evol* 36:290-300; Altschul, S, F et al (1990) *J Mol Biol* 215:403-10.

Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring

-8-

sequence pair (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighbourhood word score threshold (Altschul et al, supra). These initial neighbourhood word hits act as seeds for initiating searches to find HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extensions for the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1992) Proc. Natl. Acad. Sci. USA 89: 10915-10919) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands.

The BLAST algorithm performs a statistical analysis of the similarity between two sequences; see e.g., Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90: 5873-5787. One measure of similarity provided by the BLAST algorithm is the smallest sum probability ( $P(N)$ ), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a sequence is considered similar to another sequence if the smallest sum probability in comparison of the first sequence to the second sequence is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

-9-

Typically the homologous protein differs from the relevant protein by at least 1, 2, 5 or 10 mutations (substitutions, insertions or deletions) when compared to all of the protein or over any of the lengths of  
5 contiguous amino acids mentioned above.

The enzyme used in the process is preferably a mutant of P450<sub>cam</sub> (such as mutant of the sequence shown in table 7) or a mutant of a naturally occurring homologue of P450<sub>cam</sub>, typically of P450<sub>BM-3</sub> from *Bacillus megaterium*  
10 (such as a mutant of the sequence shown in table 8), P450<sub>terp</sub> from *Pseudomonas sp*, and P450<sub>eryF</sub> from *Saccharopolyspora erythraea*, and also P450 105 D1 (CYP105) from *Streptomyces griseus* strains. Note that the amino acid numbering shown in table 8 for P450<sub>BM-3</sub>,  
15 does not correspond to the numbering used in the description to denote mutations in this enzyme. The sequence shown in table 8 contains an additional amino acid at the N terminal. This is normally cleaved in vivo. Therefore each amino acid number shown in the  
20 table is always one more than the number used in the conventional numbering (as used in the description).

The naturally occurring homologue of P450<sub>cam</sub> (e.g. of P450<sub>BM-3</sub>) may have substantially the same activity as P450<sub>cam</sub> or P450<sub>BM-3</sub>. The homologue may be a species  
25 homologue or an allelic variant of P450<sub>cam</sub> from *Pseudomonas putida* or of P450<sub>BM-3</sub>. The amino acids in the active site of the homologue may be the same as in the active site of P450<sub>cam</sub> or of P450<sub>BM-3</sub>. Typically the amino acid at the equivalent position to 96 in P450<sub>cam</sub> is a  
30 tyrosine in the homologue.

The mutant of P450<sub>cam</sub> or of a homologue of P450<sub>cam</sub> is typically one in which amino acid 96, or the equivalent amino acid in a homologue, has been changed to an amino acid with a less polar side chain. In the case where the  
35 homologue is P450<sub>BM-3</sub> the mutant typically has a

-10-

substitution (to a less polar amino acid) at 47 and/or 51  
and/or 42 and/or 75 and/or 354 and/or 264 and/or 263  
and/or 181 and typically does not have a mutation at the  
equivalent site to 96 of P450<sub>cam</sub> (preferred mutants of  
5 P450<sub>BM-3</sub>, have at least mutations at 47 and 51, or at the  
equivalent sites in homologues).

Thus typically the substitution is to an amino acid  
which is above the original amino acid in Table 3, such  
as the preferred mutations shown in Table 4 and Table 5.

10 The 'equivalent' side chain in the homologue is one  
at the homologous position. This can be deduced by lining  
up the P450<sub>cam</sub> or P450<sub>BM-3</sub> sequence and the sequence of the  
homologue based on the homology between the two  
sequences. The PILEUP and BLAST algorithms can be used to  
15 line up the sequences. The equivalent amino acid will  
generally be in a similar place in the active site of the  
homologue as any of the specific amino acids discussed  
herein, such as amino acid 96 in P450<sub>cam</sub>.

20 The discussion below provides examples of the  
positions at which substitutions may be made in P450<sub>cam</sub>  
and P450<sub>BM-3</sub>. The same substitutions may be made at  
equivalent positions in the homologues. Standard  
nomenclature is used to denote the mutations. The letter  
25 of the amino acid present in the natural form is followed  
by the position, followed by the amino acid in the mutant  
(these positions can be correlated to the numbering shown  
in tables 7 and 8 with the proviso discussed above with  
regard to table 8 amino acid numbering). To denote  
multiple mutations in the same protein each mutation is  
30 listed separated by hyphens. The mutations discussed  
below using this nomenclature specify the natural amino  
acid in P450<sub>cam</sub> or P450<sub>BM-3</sub> but it is to be understood that  
the (same) mutation could be made to a homologue which  
has a different amino acid at the equivalent position.

35 An additional mutation is typically an amino acid

-11-

substitution at amino acid 87, 98, 101, 185, 244, 247, 248, 296, 395, 396 of P450<sub>cam</sub> (or a combination of these, for example as shown in table 4).

The following combinations of substitutions are  
5 preferred for P450<sub>cam</sub>:

(i) Substitution at position 87 to amino acids of different side-chain volume, such as substitutions (typically of F) to A, L, I and W, combined with substitutions at position 96 to amino acids of different 10 side-chain volume such as (typically Y to) A, L, F, and W. These combinations alter the space available in the upper part of the substrate pocket compared to the wild-type enzyme, for example, from Y96W-F87W (little space) to Y96A-F87A (more space), as well as the location of the 15 space, for example from one side in Y96F-F87A to the other in Y96A-F87W.

(ii) Substitution at position 96 to F combined with substitutions at positions 185 and 395. Both T185 and I395 are at the upper part of the substrate pocket, and 20 substitution with A creates more space while substitution with F will reduce the space available and push the substrate close to the haem.

(iii) Substitutions at position 96 to A, L, F, and W combined with substitutions at residues closer to the 25 haem including at 101, 244, 247, 295, 296 and 396 to A, L, F, or W. These combinations will create or reduce space in the region of the different side-chains to offer different binding orientations to substrates of different sizes. For example, the combinations Y96W-L244A and 30 Y96L-V247W will offer very different substrate pockets for the binding of R-limonene.

(iv) Triple substitutions at combinations of positions 87, 96, 244, 247, 295, 296, 395 and 396 with combinations of A, L, F, and W. The aim is to vary the size and shape 35 of the hydrophobic substrate binding pocket. For

-12-

example, the Y96A-F87A-L244A combination creates more space compared to the Y96F-F87W-V396L combination, thus allowing larger terpenes to bind to the former while restricting the available binding orientations of smaller 5 terpenes in the latter. The combinations Y96F-F87W-V247L and Y96F-F87W-V295I have comparable substrate pocket volumes, but the locations of the space available for substrate binding are very different. The combination Y96F-F87L-V247A has a slightly larger side-chain volume 10 at the 96 position than the combination Y96L-F87L-V247A, but the L side-chain at the 96 position is much more flexible and the substrate binding orientations will be different for the two triple mutants.

15 (v) The mutants with four or five substitutions were designed with similar principles of manipulating the substrate volume, the different flexibility of various side-chains, and the location of the space available in the substrate pocket for terpene binding so as to effect changes in selectivity of substrate oxidation.

20 The invention also provides the mutant of P450<sub>cam</sub> or a mutant of a homologue of P450<sub>cam</sub> (such as P450<sub>BM-3</sub>) as discussed above, excluding mutants of P450<sub>cam</sub> which only have the mutations:

25 F87A-Y96G-F193A, F87A-Y96G-F193A-C334A or T101M-T185F- V247M.

30 The mutant enzyme may be in a substantially isolated form and/or a substantially purified form, in which case it will generally comprise (e.g. about or at least) 90%, such as (e.g. about or at least) 95%, 98% or 99% of the protein in the preparation.

35 The invention also provides a polynucleotide which comprises a sequence which encodes the mutant enzyme of the invention. The polynucleotide is typically DNA or RNA, and may be single or double stranded. The polynucleotide may be able to hybridise with a

-13-

polynucleotide encoding the naturally occurring form of any mutant discussed herein (each the polynucleotide shown in table 7 or 8). It typically hybridises with the relevant polynucleotide at a level significantly above 5 background. The signal level generated by the interaction is typically at least 10 fold, preferably at least 100 fold, as intense as 'background' hybridisation. The intensity of interaction may be measured, for example, by radiolabelling the probe, e.g. with  $^{32}\text{P}$ .  
10 Selective hybridisation is typically achieved using conditions of medium to high stringency (for example 0.03M sodium chloride and 0.03M sodium citrate at from about 50°C to about 60°C).

Polynucleotides of the invention can be 15 incorporated into a recombinant replicable vector. The vector may be used to replicate the nucleic acid in a compatible host cell. Thus one method of making polynucleotides of the invention comprises introducing a polynucleotide of the invention into a replicable vector, 20 introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about replication of the vector. The vector may be recovered from the host cell. Suitable host cells are described below in connection with expression vectors.

25 Preferably, a polynucleotide of the invention in a vector is operably linked to a control sequence which is capable of providing for the expression of the coding sequence by the host cell, i.e. the vector is an expression vector.

30 The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to a coding sequence is ligated in such a way that 35 expression of the coding sequence is achieved under

-14-

conditions compatible with the control sequences.

Such vectors may be transformed into a suitable host cell to provide for expression of the mutant enzyme.

The vectors may be, for example, plasmid, virus or 5 phage vectors provided with an origin of replication, optionally a promoter for the expression of the said polynucleotide and optionally a regulator of the promoter. The vectors may contain one or more selectable marker genes, for example an ampicillin resistance gene 10 in the case of a bacterial plasmid or a neomycin resistance gene for a mammalian vector. Vectors may be used *in vitro*, for example for the production of RNA or used to transfect or transform a host cell.

Promoters and other expression regulation signals 15 may be selected to be compatible with the host cell for which the expression vector is designed. For example, *E.Coli* promoters include *lac*, *tac*, *trc*, *trp* and *T7* promoters, and yeast promoters include *S. cerevisiae* *GAL4* and *ADH* promoters, *S. pombe* *nmt1* and *adh* promoters.

20 Mammalian promoters include the metallothionein promoter which can be induced in response to heavy metals such as cadmium. The expression vectors are possible for use in insect or mammalian cells. For use in insect cells, strong baculovirus promoters such as the polyhedrin 25 promoter are preferred. For expression in mammalian cells, strong viral promoters such as the SV40 large T antigen promoter, a CMV promoter or an adenovirus promoter may also be used. All these promoters are readily available in the art.

30 Expression vectors of the invention are typically introduced into host cells using conventional techniques including calcium phosphate precipitation, DEAE-dextran transfection, or electroporation.

35 The expression vector may contain a selectable marker and/or such a selectable marker may be co-

-15-

transfected with the expression vector and stable transfected cells may be selected.

Suitable cells include cells in which the abovementioned vectors may be expressed. Such cells may be prokaryotic or eukaryotic. These include microbial cells typically bacteria such as *E. coli*, preferably the strains DH<sub>5α</sub>, JM109, NM522 and BL21DE3 or *Pseudomonas*, typically *putida*, mammalian cells such as CHO cells, COS7 cells or HeLa cells, insect cells or yeast such as *Saccharomyces*. Baculovirus or vaccinia expression systems may be used.

Cell culture can take place under standard conditions. Generally the cells are cultured in the presence of assimible carbon and nitrogen sources.

Commercially available culture media for cell culture are widely available and can be used in accordance with manufacturers instructions.

Typically the process of the invention is carried out in vitro, such as in a cell free system. The process may be carried out in vivo in a cell.

Typically, in addition to the enzyme (a) and the substrate the process of the invention is carried out in the presence of an electron transfer reductase (b), an electron transfer redoxin (c), cofactor for the enzyme and an oxygen donor. In this system the flow of electrons is typically: cofactor → (b) → (c) → (a). However particular enzymes do not require the presence of an electron reductase and electron transfer redoxin, such as P450<sub>BM-3</sub>. Although the following discussion is particularly directed to enzymes which do require a reductase or redoxin, it is applicable to enzymes which do not require these (for example the various concentrations, conditions and rates are suitable for these enzymes).

For enzymes which do require a reductase and

-16-

redoxin (b) is generally an electron transfer reductase which is able to mediate the transfer of electrons from the cofactor to (c), such as a naturally occurring reductase or a protein which has homology with a naturally occurring reductase, such as at least 70% homology; or a fragment of the reductase or homologue. Thus (b) may be derived from any of the organisms listed above from which the haem-containing enzyme may be derived. (b) is typically a flavin dependent reductase, such as putidaredoxin reductase.

(c) is generally an electron transfer redoxin which is able to mediate the transfer of electrons from the cofactor to (a) via (b). (c) is typically a naturally occurring electron transfer redoxin or a protein which has homology with a naturally occurring electron transfer redoxin, such as at least 70% homology; or a fragment of the redoxin or homologue. Thus (c) may be derived from any of the organisms listed above from which the haem-containing enzyme may be derived. (c) is typically a two-iron/two sulphur redoxin, such as putidaredoxin.

The cofactor is any compound capable of donating an electron to (b), such as NADH. The oxygen donor is any compound capable of donating oxygen to (a), such as dioxygen.

In the process the concentration of (a), (b) or (c) is typically from  $10^{-8}$  to  $10^{-2}M$ , preferably from  $10^{-6}$  to  $10^{-4}M$ . Typically the ratio of concentrations of (a): (b) and/or (a): (c) is from 0.1:01 to 1:10, preferably from 1:0.5 to 1:2, or from 1:0.8 to 1:1.2. Generally the process is carried out at a temperature and/or pH at which the enzyme is functional, such as when the enzyme has at least 20%, 50%, 80% or more of peak activity. Typically the pH is from 3 to 11, such as 5 to 9 or 6 to 8, preferably 7 to 7.8 or 7.4. Typically the temperature is 15 to 90°C, such as 25 to 75°C or 30 to 60°C. In one

-18-

following:

H<sub>2</sub>N-P450<sub>cam</sub>-TDGTSST-putidaredoxin reductase-TDGASSS-putidaredoxin-COOH,

5 H<sub>2</sub>N-P450<sub>cam</sub>-TDGTRPGPGPGPGPSST-putidaredoxin reductase-TDGASSS-putidaredoxin-COOH,

H<sub>2</sub>N-P450<sub>cam</sub>-TDGTRPGPGPGPGPGPSST-putidaredoxin reductase-TDGASSS-putidaredoxin-COOH,

H<sub>2</sub>N-putidaredoxin reductases-TDGASSS-putidaredoxin-PLEL-P450<sub>cam</sub>-COOH.

10 However it is understood that the excluded *E.Coli* DH5 $\alpha$  cells can be used to produce the libraries discussed below.

A preferred cell (second type) is a cell which expresses:

15 (a) (i) P450<sub>BM-3</sub>, or a fragment thereof; or  
(ii) a naturally occurring homologue of P450<sub>BM-3</sub> or a fragment thereof; or  
(iii) a mutant P450<sub>BM-3</sub>, or a mutant homologue of thereof.

20 The cell provided by the invention is typically a cell from the species mentioned above in which the nucleotide of the invention can be expressed. The cell may be a mutator cell. Such a cell is generally deficient in one or more of the primary DNA repair pathways (such as *E.Coli* pathways mutS, mutD or mutT, or their equivalents in another organism), and thus has a high mutation rate. Simply culturing such cell leads to the DNA encoding (a) to become mutated. The cell may be of *E.Coli* XL1 Red mutator strain.

25 The cell of the invention may be in a substantially isolated form and/or substantially purified form, in which case it will generally comprise (e.g. at least or about) 90%, such as (e.g. at least or about) 95%, 98% or 99% of the cells or the mass (normally measured in terms of dry mass) of the preparation.

-17-

embodiment the process is carried out in the presence of a substance able to remove hydrogen peroxide by-product (e.g. a catalase).

5 Alternatively the process of the invention could be carried out in the presence of the enzyme, substrate and an oxygen atom donor, such as hydrogen peroxide or t-butylhydroperoxide. Thus, the process could be carried out using the peroxide shunt.

10 Typically in the process at least 20 turnovers/min occur, such as at least 50, 100, 200, 300, 500 or more turnovers (turnover is measured as nanomoles of product formed per nanomole of enzyme).

The invention also provides several types of cells. The first type expresses :

15 an enzyme which can be used in the process which in its naturally occurring form has an electron transfer reductase domain; or expresses  
  
(a) the mutant haem-containing enzyme which is used in the process of the invention;  
20 (b) an electron transfer reductase; and  
(c) an electron transfer redoxin.

The second type of cell expresses:

25 (a) (i) P<sub>450<sub>cam</sub></sub> or a fragment thereof; or  
(ii) a naturally occurring homologue of P<sub>450<sub>cam</sub></sub> or a fragment thereof; or  
(iii) a mutant of P<sub>450<sub>cam</sub></sub>; or  
(iv) a polypeptide which has at least 70% amino acid homology with (i) or (ii) and optionally has any of the combination of mutations discussed herein; and  
30 (b) an electron transfer reductase; and  
(c) an electron transfer redoxin:  
excluding an *E.Coli* DH5 $\alpha$  cell in which the only  
35 mutants of P<sub>450<sub>cam</sub></sub> which are expressed are amongst the

-19-

The cell may be one which does not naturally express (a), (b) or (c). The cell be one in which (a), (b) or (c) are expressed at a higher level than in the naturally occurring cell. (a) may originate from the  
5 same organism as (b) or (c).

In the cell (a), (b) and (c) may be expressed from the same vector, or may be expressed from different vectors. They may be expressed as three different polypeptides. Alternatively they may be expressed in the  
10 form of fusion proteins. Typically components (a), (b) and (c) are all present in the same fusion protein. Alternatively only two of the components, preferably (b) and (c), may be present in the fusion protein. Typically the components are contiguous in the fusion protein and  
15 there is no linker peptide present.

Alternatively a linker may be present between the components. The linker generally comprises amino acids that do not have bulky side chains and therefore do not obstruct the folding of the protein subunits. Preferably  
20 the amino acids in the linker are uncharged. Preferred amino acids in the linker are glycine, serine, alanine or threonine. In one embodiment the linker comprises the sequence N-Thr-Asp-Gly-Gly-Ser-Ser-Ser-C. The linker is typically from at least 5 amino acids long, such as at  
25 least 10, 30 or 50 or more amino acids long.

The first type of cell may be obtained by transforming or transfecting a host cell with a polynucleotide or vector of the invention.

The mutant enzyme of the invention may be prepared  
30 by a process comprising cultivating the first type of cell under conditions to provide for expression of the said mutant enzyme, and optionally recovering the expressed mutant enzyme.

The process of the invention may be carried out in  
35 the first type of cell of the invention or in the second

-20-

type of cell if it is able to oxidize the substrate, or a medium containing it. Generally such a process comprises providing the substrate in the cell, allowing the substrate to be oxidized in the process of the invention,  
5 and optionally obtaining the oxidation product therefrom, e.g. by extraction. The substrate is typically provided in the cell by adding the substrate to the outside of the cell and allowing it to enter the cell. Alternatively the substrate could be synthesized in the cell from a  
10 precursor.

The invention also provides a process for making a library of mutants of P450<sub>cam</sub> or mutants of a homologue of P450<sub>cam</sub> comprising contacting the second type of cell with a mutagen and/or when the cell is a mutator cell  
15 culturing the cell in conditions in which mutants are produced. The mutagen may be contacted with the cell prior to or during culturing of the cell. Thus the mutagen may be present during replication of the cell or replication of the genome of the cell.

20 The mutagen generally causes random mutations in the polynucleotide sequence which encodes (a). The mutagen is typically a chemical mutagen, such as nitrosomethylguanidine, methyl- or ethylmethane sulphonic acid, nitrite, hydroxylamine, DNA base analogues, and  
25 acridine dyes, such as proflavin. It is typically electromagnetic radiation, such as ultra-violet radiation at 260 nm (absorption maximum of DNA) and X-rays. It is typically ionising radiation.

Typically the library will be in the form of cells  
30 which are derived from cells of the invention by mutagenesis and which cells comprise the mutant enzymes. Generally each cell will express only one particular mutant enzyme. The library typically comprises at least 500 mutants, such as at least 1,000 or 5,000 mutants,  
35 preferably at least 10,000 different mutants.

-21-

The library typically comprises a random population of mutants. The library may undergo one or more rounds of selection whilst being produced and therefore may not comprise a random population. Between rounds of  
5 selection the cells in the library may be allowed to replicate, and they may also be contacted with a mutagen.

A mutant can be selected from the library based on a particular property of the mutant. The property may comprise one or more of the following characteristics:

10 (i) the ability to oxidize a particular substrate; optionally to a particular oxidation product or to a product with a particular activity.  
(ii) the ability to carry out the oxidation of substrate at an increased rate,  
15 (iii) a reduced oxidation activity towards a particular substrate,  
(iv) a reduction in the production of a particular substrate.

Typically the activity of the product in (i) is blocking the action of an agent which is lethal to the cells of the library. This can be selected by growing the library in the presence of the agent. The agent is typically expressed within the cells of the library.

The activity may be the binding of the product to a particular substance, such a protein. The substance is typically present in the cell of the library, and/or is typically a disease-causing or therapeutic target. An indicator which binds the substance is typically used to detect binding of the product to the substance. In one embodiment the indicator is able to bind the substance and has a property which changes upon binding, e.g. a colour change. Product which displaces the indicator from the substance can thus be detected by measuring changed in the property.

35 The invention also provides a method of making a

-22-

library of oxidation products comprising providing a substrate to the library of mutant enzymes and allowing oxidation of the substrate.

Products produced in the process of the invention, or identified, selected, made or designed using the library could be used in therapy or diagnosis. Thus the invention provides a method of treating a host suffering from a disease, which method comprises administering to the host a therapeutically effective amount of the product. The condition of a patient suffering from the disease and in need of the product can therefore be improved by administration of the product. The product can also be given as a prophylactic, typically to a host which is at risk from or susceptible to the disease.

The invention provides the product for use in a method of treatment of the human or animal body by therapy. The invention also provides the product for use in a diagnostic method practiced on the human or animal body. The invention also provides use of the product in the manufacture of a medicament to treat a disease.

The formulation of the product for use in preventing or treating infection by an organism will depend upon factors such as the nature of the product identified, whether a pharmaceutical or veterinary use is intended, etc. In order to be administered to a patient, the compound will be provided in the form of a pharmaceutical composition containing the product and a pharmaceutically acceptable carrier or diluent. Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline. Typical oral dosage compositions include tablets, capsules, liquid solutions and liquid suspensions. For example it may be formulated for parenteral, intravenous, intramuscular, subcutaneous, transdermal or oral administration.

The dose of product may be determined according to

-23-

various parameters, especially according to the substance used; the age, weight and condition of the patient to be treated; the route of administration; and the required regimen. A physician will be able to determine the  
5 required route of administration and dosage for any particular patient. A suitable dose may however be from 0.1 to 100 mg/kg body weight such as 1 to 40 mg/kg body weight, for example, to be taken from 1 to 3 times daily.

10 The invention is illustrated by the accompanying drawings which show the gas chromatography results for various oxidation reactions. In the drawings unless stated otherwise the y-axis shows mVolts and the x-axis shows Time (in minutes).

In the drawings:

15 Figure 1 shows the oxidation of camphor by the C334A mutant of P450<sub>cam</sub> (expressed from plasmid SGB++). Lines A, B, C, D and E represent camphor turnover at 2, 10, 20, 40 and 100 minutes. The 5.28 peaks is camphor, 11.82 is 5-exo-hydroxycamphor, 7.45 is 5-ketocamphor and  
20 the 16.07 peak is the internal standard.

Figure 2 shows R- and S- limonene with wild type P450<sub>BM-3</sub>.

Figure 3 shows NADH consumption by wild type and mutant P450<sub>BM-3</sub>.

25 Figure 4 shows the whole cell E. coli oxidation of α-pinene by the Y96F-F87W-V247L mutant expressed by plasmid pCWSGB+.

The invention is also illustrated by the Examples:

Example 1

30 Expression of mutants for *in vitro* work.

The P450<sub>cam</sub> enzymes were expressed using the vector pRH1091 (Baldwin, J.E., Blackburn, J.M., Heath, R.J., and Sutherland, J.D. *Bioorg. Med. Chem. Letts.*, 1992, 2, 663-668.) which utilised the trc promoter (a fusion of the trp and lac promoters). This vector incorporates a strong

-24-

ribosome binding site (RBS) and the gene to be expressed is cloned using an *Nde* I site on the 5' end of the gene. We used *Hind* III as the cloning site at the 3' end of the *camC* gene. The procedure for protein expression is as  
5 follows: Cells are grown at 30°C until the OD<sub>600nm</sub> reaches 1.0 - 1.2, the temperature is increased to 37°C and camphor added as a 1 M stock in ethanol to a final concentration of 1 mM. The culture is allowed to incubate at 37°C for another 6 hours. The P450<sub>cam</sub> protein is  
10 expressed to high levels in the cytoplasm and the cells take on a red to orange-red colour.

We have also prepared a variant of pRH1091 (by PCR) which has a extra *Xba* I site between the RBS and the *Nde* I site. This is important because *Nde* I is not unique in  
15 M13, and this restriction site is also present in the reductase gene as well as the backbone of the pGLW11 vector used for the *in vivo* system. *Xba* I is unique in the polylinker region of M13, but absent in the genes of all three proteins in the P450<sub>cam</sub> system and in the  
20 expression vectors. It therefore allows the *camC* gene to be moved between the mutagenic and expression vectors.

The P450<sub>BM-3</sub> enzyme from *Bacillus megaterium* was expressed using either the pGLW11 or pCW vectors. The recombinant plasmid with the P450<sub>BM-3</sub> gene inserted into  
25 either of these vectors were transformed into *E. coli* strain DH5α and grown under ampicillin selection. A single colony was then grown at 30°C in LB media supplemented with ampicillin until the OD at 600 nm reached ca. 1, and protein expression was induced by  
30 adding IPTG from a 1 M stock to a final concentration of 1mM. After 6-8 h, cells were harvested by centrifugation and the expression levels were high, as indicated by an orange-red coloration of the cells.

-25-

How the mutants were made.

Oligonucleotide-directed site-specific mutagenesis was carried out by the Kunkel method (Kunkel, T. A. *Proc. Natl. Acad. Sci. USA* 1985, **82**, 488-492) using the Bio-Rad Mutagen kit and by PCR using the QuikChange kit from Stratagene. The recommended procedure for the Kunkel method is summarised as follows. An M13 mp19 subclone of the *camC* gene encoding P450<sub>cam</sub> was propagated in the *E. coli* strain CJ236. This strain has the *dut*<sup>-</sup>*ung*<sup>-</sup> phenotype and thus will tolerate the inclusion of uracil in place of thymine in DNA molecules. After three cycles of infection, uracil-containing single stranded (USS) M13 DNA was readily isolated by phenol extraction of mature M13 phage particles excreted into the growth medium. The mutagenic oligonucleotide (or oligonucleotides) were phosphorylated with T4 polynucleotide kinase and then annealed to the USS template. The four nucleotides, DNA polymerase, DNA ligase, ATP and other chemical components were added and the second strand was synthesised *in vitro*. The double stranded form thus obtained was transformed into the *dut*<sup>+</sup> *ung*<sup>+</sup> *E. coli* strain MV1190, which should degrade the uracil-containing template strand and propagate the mutant strand synthesised *in vitro*. Plaques were picked and phages of possible mutants grown in *E. coli* strains MV1190 or TG1. The single-stranded DNA from these were sequenced to determine whether the mutagenesis reaction was successful. The mutagenic efficiency was 50 - 80%. The mutant *camC* gene is excised from the M13 subclone by restriction digest with *Nde* I and *Hind* III, and the fragment of appropriate size is ligated to the backbone of the expression vector prepared by a similar *Nde* I/*Hind* III digest.

The QuikChange kit relies on the property of the *Dpn* I restriction enzyme which selectively cleaves methylated

-26-

DNA. The mutation is introduced by PCT using double stranded plasmid DNA, and hence no single stranded template preparations are necessary. The PCR reaction is carried out with two oligonucleotides, one of which binds  
5 to the coding strand and the other to the sense strand. Each oligonucleotide contains a short stretch of polynucleotide complementary to either side of the mutation site. After *in vitro* synthesis by PCR using non-methylated dNTP's, plasmid DNA with overlapping nicks  
10 in each strand were digested with *Dpn* I to remove the starting template selectively - plasmid DNA isolated from most *E. coli* strains contain methylated bases but the newly synthesised DNA do not have methylated bases.  
15 After the digest the DNA is transformed into supercompetent *E. coli* XL1 Blue cells and propagated. The plasmid DNA from potential mutants which grow on agar plates under antibiotic selection were isolated and sequenced to confirm mutagenesis. The cells can then be used for protein expression once the entire sequence of  
20 the new mutant was confirmed to ensure that there were no spurious mutations.

Multiple mutants were prepared either by further mutagenesis, also by the Kunkel method, or where the location of the sites in the sequence permits, simple  
25 cloning steps. There are two unique restriction sites within the *camC* gene which are absent from the expression vector. One is *Sph* I which spans residues 121 - 123, and the other is *Sal* I which spans residues 338 and 339. Therefore, all mutations at, for example, residues 87,  
30 96, 98, and 101 are readily combined with mutations at higher number residues by ligating appropriate fragments from restriction digests of mutant *camC* genes with *Nde* I/*Sph* I and *Sph* I/*Hind* III and the backbone fragment from a *Nde* I/*Sph* I digest of the expression vector. Mutations

-27-

at, for example, 395 and 396 can be similarly incorporated by digests in which *Sph* I is replaced with *Sal* I.

5       The rationale for introducing the unique *Xba* I site  
is now clear: many mutants with multiple mutations were  
prepared by the cloning procedure above. Without the *Xba*  
I site it would be impossible to clone the gene for these  
multiple mutants from the expression vector back into M13  
for further rounds of mutagenesis. Of course these  
10      problems could be overcome by doing mutagenesis by PCR,  
for example.

Example 2

Substrate oxidation protocol: *in vitro* reactions

15	Component	Final concentration
	P450 <sub>cam</sub> enzyme	1 μM
	Putidaredoxin	10 μM
	Putidaredoxin reductase	1 μM
	Bovine liver catalase	20 μg/ml
20	KCl	200 mM
	Substrate	Typically 1 mM
	NADH	250 - 400 μM

\* 50 mM Tris-HCl buffer pH 7.4 is added to make up  
25 the volume.

\* Temperature controlled at 30°C, optional.

\* The NADH turnover rate could be determined by monitoring the absorbance at 340 nm with time.

30      \* Catalase does not catalyse the substrate oxidation reactions but rather it is present to remove any hydrogen peroxide by-product which could otherwise denature the P450<sub>cam</sub>.

The method can be increased in scale to, for example, 20 ml total incubation volume to allow  
35      purification of sufficient products by HPLC for

-28-

spectroscopic characterisation. Fresh substrate (1 mM) and NADH (1 - 2 mM) are added periodically, such as every 20 minutes in a total reaction time of, typically, 3 hours.

5

Example 3

The in vivo system

10 The *in vivo* systems were expressed using the vector pGLW11, a derivative of the plasmid pKK223 (Brosius, J. and Holy, A. *Proc. Natl. Acad. Sci. USA*, 1984, 81, 6929-6933). Expression is directed by the tac promoter and the vector incorporates a gene conferring resistance to the antibiotic ampicillin.

15 Two systems were constructed. The first one expressed the electron transfer proteins putidaredoxin reductase (*camA* gene) and putidaredoxin (*camB* gene) as a fusion protein with a seven amino acid peptide linker, and the P450<sub>cam</sub> enzyme (*camC* gene) was expressed by the same vector but it was not fused to the electron 20 proteins. The second system expressed the three proteins as separate entities in the *E.Coli* host. Both systems were catalytically competent for substrate oxidation *in vivo*.

25 The general strategy was as follows. The genes for the three proteins were cloned using *Eco RI* and *Hind III* as flanking sites, with *Eco RI* at the 5' end. For both *in vivo* systems there are restriction sites between the genes, including between the reductase and redoxin genes in the fusion construct. These restriction sites were 30 introduced by PCR, as detailed below. The first task, however, was to carry out a silent mutation to remove the *Hind III* site within the *camA* gene for the reductase. The AAGCTT *Hind III* recognition sequence in the *camA* gene was changed to AAGCCT, which is a silent mutation because

-29-

GCT and GCC both encode alanine. The gene was completely sequenced to ensure that there were no spurious mutations.

5      1. The fusion protein system

1.a Manipulation of the *camA* gene by PCR

For the *camA* gene the primer below was used at the 5' end of the gene to introduce the *Eco* RI cloning site and to change the first codon from GTG to the strong start codon ATG.

5'- GAG ATT AAG AAT TCA TAA ACA CAT GGG AGT GCG TGC CAT ATG AAC GCA AAC

*Eco* RI                          RBS                          |-*camA*

15        At the 3' end of *camA* the primer was designed such that 15 bases are complementary to nucleotide sequence of the last five amino acid residues of *camA*. The stop codon immediately after the GCC codon for the last amino acid was removed, and then part of a seven amino acid linker (Thr Asp Gly Gly Ser Ser Ser) which contained a *Bam* HI cloning site (GGATCC = Gly Ser) was introduced. The coding sequence was thus:

5'- GAA CTG AGT AGT GCC ACT GAC GGA GGA TCC TCA TCG-3'

25        *camA*                          - Thr Asp Gly Gly Ser  
    |*Bam* HI|

The primer sequence shown below is the reverse complement used for PCR:

30        5'- CGA TGA GGA TCC TCC GTC AGT GGC ACT ACT CAG TTC-3'

1.b Manipulations of the *camB* gene by PCR

For the *camB* gene the primer at the 5' end incorporated the second half of the peptide linker

-30-

between the reductase and redoxin proteins, and the restriction site *Bam* HI for joining the two amplified genes together.

5' - TCA TCG **GGA** TCC TCA TCG **ATG** TCT AAA GTA GTG TAT-3'

5            Gly Ser Ser Ser | - *camB*  
              |*Bam* HI|              Start

At the 3' end of *camB* the primer incorporates 12 nucleotides complementary to the end of *camB* followed by the stop codon TAA, a 6 nucleotide spacer before the GGAG ribosome binding site. *Xba* I and *Hind* III sites were then added to allow cloning of the *camC* gene when required. The sequence of the coding strand was therefore:

15 5' - CCC GAT AGG CAA TGG **TAA** TCA TCG **GGAG** TCT **AGA** GCA TCG **AAG** CTT TCA TCG-3'

CamB      -|stop                  RBS *Xba* I              *Hind* III

The primer shown below is the reverse complement used for PCR:

5' -CGA TGA AAG CTT CGA TGC TCT AGA CTCC CGA TGA TTA CCA TTG CCT ATC GGG -3'

25 **1.c Preparation of the full fusion construct**

The *camA* and *camB* genes were amplified by the PCR using the primers described above. The new *camA* was digested with *Eco* RI and *Bam* HI, while the new *CamB* was digested with *Bam* HI and *Hind* III. The pGLW11 expression vector was digested with *Eco* RI and *Hind* III. All three were purified by agarose gel electrophoresis and the three gel slices containing the separate fragments were excised from the gel and ligated together, and then transformed into *E.Coli* DH5 $\alpha$ . Successful ligation of all the fragments were confirmed by a series of restriction

-31-

digestion experiments, especially the presence of the new and unique *Xba* I site. The entire sequence of the insert from the *Eco* RI site to the *Hind* III site was determined to ensure that all the sequences were correct.

5       The new plasmid, named pSGB<sup>F</sup> was transformed into *E.Coli* and expression of the reductase and redoxin proteins was induced by IPTG. When a purified P450<sub>cam</sub> enzyme was added to the cell-free extract, substrate oxidation was observed for a variety of substrates.

10       When the *camC* gene is cloned into the pSGB<sup>F</sup> plasmid using the *Xba* I and *Hind* III restriction sites, the new recombinant plasmid thus generated expresses the reductase and redoxin as a fusion protein and the P450<sub>cam</sub> enzyme as a operate entity both from the same mRNA molecule. This *in vivo* system is catalytically competent for terpene oxidation in whole cells.

2.       **The *in vivo* system with the protein expressed  
20       separately**

**2.a     The basic strategy**

25       The starting point of the preparation of this *in vivo* system was the recombinant plasmid used to express the *camA* gene for putidaredoxin reductase. The *camA* gene was cloned into the pGLW11 plasmid using the *Eco* RI and *Bam* HI restriction sites, with *Eco* RI being at the 5' end of the gene. Conveniently the polylinker region of the pGLW11 vector has a *Hind* III site downstream of the *Bam* HI site. The *camB* gene was therefore manipulated by PCR such that it can be cloned into pGLW11 using the *Bam* HI and *Hind* III sites. This new plasmid expresses the reductase and redoxin as separate proteins.

The *camB* gene was cloned into pUC118 by the *Bam* HI

-32-

and *Hind* III cloning sites to express putidaredoxin for our general *in vitro* substrate oxidation work. Therefore, the PCR primer at the 3' end of the *camB* gene was designed to introduce a ribosome binding site and the 5 *Xba* I restriction site upstream of the *Hind* III site so that the *camC* gene can be inserted downstream of *camB* using the *Xba* I and *Hind* III sites. Therefore the three genes were cloned without fusion in the pGLW11 expression vector and arranged in the order 5'-*camA-camB-camC*-3', 10 and each gene has its own RBS to initiate protein synthesis.

### 2.b Manipulations of the *camB* gene

We used the internal and unique restriction site *Mlu* I (recognition sequence ACGCGT) within the *camB* gene as the starting point so that the PCR product has a different size from the PCR template fragment. The primers were as follows:

20 5'- TCA TCG **ACG CGT** CGC GAA CTG CTG-3'

where the *Mlu* I site is in bold.

The desired coding sequence at the 3' end of the 25 *camB* gene was:

5'- CCC GAT AGG CAA TGG **TAA** GTA GGT GAA TAT CTA ATC CCC ATC  
*camB* -|stop

TAT GCG CGA GTG **GAG** TCT **AGA** GTT CGA-3'

30 RBS *Xba* I

After the stop codon there is a 35 base spacer before the RBS which is used to initiate the synthesis of the P450<sub>cam</sub> enzyme. The *Xba* I cloning site is located

-33-

within the spacer between the RBS and the start codon (not in this primer) of the *camC* gene. The PCR primer used was the reverse complement of the sequence above. The PCR was carried out and the amplified fragment of the appropriate size was purified by agarose gel electrophoresis and the gel slice excised.

One extra step was necessary to complete the construction of the new plasmid. The plasmid for the fusion protein *in vivo* system was digested with *Mlu* I and *Hind* III restriction enzymes, purified by agarose gel electrophoresis, and the gel slice for the small *camB* fragment excised. The pUC118 plasmid for *camB* expression was similarly digested, and the gel slice for the backbone was excised. By ligating the two fragments together we prepared a new pUC118-based plasmid which had an *Xba* I site followed by an *Hind* III site downstream of the stop codon of *camB*. This new plasmid was digested with the *Mlu* I and *Xba* I enzymes and the backbone was ligated with the new *camB* fragment described above to generate a plasmid with the following arrangement of the key components:

..*lac* Promoter..*Bam* HI..*camB* gene..*spacer*..*RBS*..*Xba* I..*Hind* III..

25     **2.c Preparation of the *in vivo* system plasmid**

Once the modified *camB* with the *Xba* I and *Hind* III restriction sites and appropriate spacers were prepared, the *in vivo* system was constructed by cloning this into the pGLW11-based plasmid used to express the *camA* gene (reductase protein) using the *Bam* HI and *Hind* III sites. The new *in vivo* system vector has the following arrangement of the key components:

..*tac* Promoter..*Eco* IRI..*RBS*..*camA* gene..*spacer*..*Bam*

-34-

HI..RBS..**camB gene..spacer..RBS..Xba I.. Hind III..**

This new plasmid, named pSGB<sup>+</sup>, was transformed into *E.Coli* and expression of the reductase and redoxin proteins was induced by IPTG. When a purified P450<sub>cam</sub> enzyme was added to the cell-free extract, substrate oxidation was observed for a variety of substrates.

When the *camC* gene is cloned into this pSGC<sup>+</sup> plasmid using the *Xba* I and *Hind* III restriction sites, the new recombinant plasmid thus generated will express the three proteins separately, each under the direction of its own RBS but from the same mRNA molecule. Thus constitutes the *in vivo* system used in the vast majority of our terpene oxidation work.

15

### 3. Introduction of an *Xba* I site into pRH1091

This is the final step to enable the *camC* gene to be cloned into the *in vivo* systems by the two cloning sites *Xba*I and *Hind* III. The *Xba* I site was added by PCR of the entire pRH1091 plasmid using two primers. The presence of these two sites will also enable cloning of the *camC* gene into M13 since both *Xba* I and *Hind* III are unique in *camC* and M13.

The primers shown below maintain the *Hind* III cloning site AAGCTT:

5'-TCA TCG **AAG CTT GGC TGT TTT-3'**

*Hind* III |- vector

30 At the other end the coding sequence desired was:

5'-ACA ATT TCA CAC **AGGA TCT AGA C CAT ATG TCA TCG AAG CTT TCA TCG-3'**

Vector -|RBS *Xba* I      *Nde* I      *Hind* III

-35-

This sequence maintained the *Nde* I and *Hind* III sites but the new *Xba* I site was introduced upstream of the *Nde* I site. The PCR primer used was the reverse complement of the desired sequence:

5

5'-CGA TGA AAG CTT CGA TGA CAT ATG GTC T AGA TCCT GTG TGA AAT  
TGT-3'

10 The PCR product was then purified by agarose gel electrophoresis, digested with *Hind* III and circularised with T4 DNA ligase. Success of the PCR method was indicated by the presence of a new and unique *Xba* I site in plasmid DNA isolated from transformants.

15 4. Cloning of *camC* into the *in vivo* systems

All existing *camC* mutants were cut out of pRH1091-based expression plastids with *Nde* I and *Hind* III. The new vector is similarly cut with the same restriction enzymes and the *camC* gene cloned into this plasmid with 20 T4 DNA ligase. This DNA is transformed into *E.Coli* JM109 which then may be grown to express P450<sub>cam</sub>.

The *camC* gene is excised from the new vector using *Xba* I and *Hind* III restriction enzymes and cloned into either the *in vivo* vector systems or M13mp19 for 25 mutagenesis.

5. *In vivo* expression and substrate turnover

For protein expression, cells are grown in LBamp medium (tryptone 10 g/litre, yeast extract 5 g/litre, 30 NaCl 10 g/litre, 50 µg/ml ampicillin) at 30°C until the OD<sub>600nm</sub> reaches 1.0 - 1.2. IPTG (isopropyl-β-D-thiogalactopyranoside) was added to a final concentration of 1 µM (from a 1 M stock in H<sub>2</sub>O) and the culture was incubated at 30°C overnight.

-36-

For simple screening the substrate can be added to culture and the incubation continued. However, due to impurities from the culture media the cells were generally washed twice with 0.5 vol. of buffer P, (KH<sub>2</sub>PO<sub>4</sub> 6.4 g, K<sub>2</sub>HPO<sub>4</sub>.3H<sub>2</sub>O 25.8 g, H<sub>2</sub>O to 4 litres, pH 7.4) and resuspended in 0.25 vol. oxygen saturated buffer P containing 24 mM glucose. Substrate was added to 1 mM and the incubation continued at 30°C. The reaction was allowed to run for 24 hours with periodic additions of substrate and glucose.

The reaction was analysed by extracting 1 ml of the incubation mixture with 250 µl of ethylacetate. After centrifuging in a microcentrifuge at 13,000 g for 2 minutes, 2 µl of the organic extract was injected onto a 0.25 mm x 30 m DB-1 gas chromatography column in a Fisons GC 8000 series gas chromatograph. The samples were carried through the column using helium carrier gas and the compounds present were detected using a flame ionisation detector.

A variety of temperature programmes were used for different substrate to resolve turnover products.

#### Monoterpenes

25	Injector temperature	150 °C
	Detector temperature	250 °C
	Oven temperature	120 °C for 15 min → 200 °C at 25 °C/min, 200 °C for 1 min.

#### Sesquiterpenes

30	Injector temperature	250 °C
	Detector temperature	250 °C
	Oven temperature	150 °C → 230 °C at 5 °C/min, 230 °C for 1 min.

35 Results for particular oxidation reactions are shown

-37-

in table 6 and in the Figures.

Figure 1 shows the result of an oxidation reaction with camphor. The 5-ketocamphor arises from further oxidation of 5-exo-hydroxycamphor. As can be seen there 5 is surprisingly little of the further oxidation occurring in the presence of camphor.

Example 4

A second *in vivo* expression system

10 The cluster of genes for the expression of the three proteins of the P450<sub>cam</sub> system, as described in Example 3, were also expressed in whole *E. coli* cells using the pCW vector. This vector utilises two tac promoters arranged in line to increase protein expression. It has a RBS, 15 and contains the gene conferring resistance to the antibiotic ampicillin (Barnes, H.J. *Methods Enzymol.* 1996, 272, 3-14).

Both methods of expressing catalytically competent P450<sub>cam</sub> systems described in Example 3 were successful 20 with the pCW vector. Thus the fusion system, where putidaredoxin reductase and putidaredoxin were expressed as a fusion protein with an oligopeptide linker, but the P450<sub>cam</sub> monooxygenase was expressed but not fused to the electron transfer proteins. The second system expressed 25 all three proteins as separate entities in the same *E. coli* host.

**1. The fusion protein system**

A new plasmid was constructed by cloning the gene 30 for the fusion of electron transfer proteins into pCW so that different P450<sub>cam</sub> mutants could be introduced into the system by cloning. The 5' end oligonucleotide used for the PCR amplification of the *cam A* gene introduced not only the Eco RI site for cloning into the pGL W11

-38-

vector but also a *Nde* I site which spans the ATG start codon of the gene (see Example 3, section 1a). In the pCW vector there is a *Nde* I site positioned downstream of the RBS for cloning of the gene to be expressed. The pGL  
5 W11 vector containing the *camA-camB* fusion gene was digested with *Nde* I and *Hind* III, and the insert purified by agarose gel electrophoresis. The pCW vector system was also digested with these two enzymes and the linearised vector purified by the same method. The two  
10 fragments were ligated with DNA ligase to generate the new pCWSGB<sub>F</sub> plasmid based on the pCW vector and which expressed the fusion of the electron transfer proteins. The insert excised from the pGL W11-based plasmid already contained a RBS for protein expression and an *Xba* I site  
15 just upstream of the *Hind* III site (see Example 3, section 2.c), so that the *cam C* gene encoding P450<sub>cam</sub> mutants can be cloned using these two sites and expressed off the RBS. Therefore genes encoding the P450<sub>cam</sub> mutants can be excised from the modified pRH system and cloned  
20 into the new pCWSGB<sub>F</sub> plasmid using the *Xba* I and *Hind* III sites.

## 2. The three proteins expressed separately

This system was generated in exactly the same way as  
25 for the fusion system. Thus the pSGB+ plasmid was digested with the *Nde* I and *Hind* III restriction enzymes and the insert cloned into the pCW vector. This new plasmid pCWSGB+ expressed putidaredoxin reductase and putidaredoxin as separate entities off the twin tac  
30 promoters of the pCW vector. The P450<sub>cam</sub> mutants were introduced into this vector using the *Xba* I and *Hind* III sites.

## 3. In vivo expression and substrate turnover

- 39 -

The conditions described below were used for test purposes in shake flasks in a laboratory and were not optimised. Under proper fermenter conditions with higher expression and biomass the final yield of products will  
5 be much increased.

*E. coli* DH5 $\alpha$  cells harbouring either of the catalytically competent P450<sub>cam</sub> systems were grown from a single colony on an agar plate in 1 L of LBamp medium at 30 °C until OD<sub>600nm</sub> reached ca. 1. IPTG was added to 1 mM  
10 final concentration (from a 1 M stock in water) and the culture grown for a further 6 h. The final OD<sub>600nm</sub> were in the range 2.0 - 2.5. Cells were harvested by centrifugation at 5000 g and washed once with 40 mM phosphate buffer, pH 7.4. The cell pellet was  
15 resuspended in 500 ml of 40 mM phosphate buffer, pH 7.4. Glucose was added as a 2 M stock to a final concentration of 100 mM, and 1 mL of the substrate ( $\alpha$ -pinene or R-limonene) was added to start the reaction. The mixture  
20 was shaken in an open 2 L conical flask in an orbital incubator at 200 rpm. More glucose was added every 24 h (100 mM final concentration based on a 500 mL volume, from a 2 M stock) and more substrate (1 mL) was added every 12 h. The progress of the reaction was monitored  
25 by GC and the whole cell system was active for at least 5 days at ambient temperatures and the minimum yield at the end of day 5, as assayed by extraction of the reaction medium with chloroform and analysing by GC, was 100 mg of products without accounting for volatilisation of products into the atmosphere and condensation on the  
30 flask above the liquid level. In addition, no compounds arising from further hydroxylation at another carbon atom were observed when the substrate was present.

-40-


Example 5

In vitro and in vivo substrate oxidation by P450<sub>BM-3</sub>






5 In a typical reaction *in vitro* (optional 30°C temperature control) the 1.5 mL incubation mixture contained 40 mM phosphate buffer, pH 8.0, 1 µM P450<sub>BM-3</sub>, 50 µg/mL of catalase, and terpene substrates were added as a 1 M stock in ethanol to a final concentration of 2 mM. NADPH was added typically to 400 µM final concentration, and the rates of reaction could be 10 monitored at 340 nm. After all the NADPH had been consumed, the mixture was extracted by vortexing with 0.5 mL of chloroform, the phases separated by centrifugation, and the organic phase could be analysed by GC using the programs described in Example 3.

15 Catalase does not catalyse the substrate oxidation reaction but rather it is present to remove any hydrogen by-product which could otherwise denature the enzyme. The method can be increased in scale to, for example, 20 mL total incubation volume to allow purification of 20 sufficient produces by HPLC for spectroscopic characterisation. Fresh substrate (1 mM) and NADPH (1-2 mM) are added periodically, such as every 20 minutes in a total reaction time of, typically 3 hours.



25 Since the P450<sub>BM-3</sub> enzyme is catalytically self-sufficient, i.e., both the monooxygenase and electron transfer domains are in a single polypeptide, the enzyme as expressed in *E. coli* can be used for whole cell, *in vivo* substrate oxidations. The procedure described under Example 3 for *in vivo* substrate oxidation by the P450<sub>cam</sub> 30 enzyme can also be used for the P450<sub>BM-3</sub> enzyme.




Limonene

 $\alpha$ -pinene $\beta$ -pinene $\alpha$ -terpinene $\gamma$ -terpinene


(+)-sabinene

(-)- $\alpha$ -thujene


myrcene



nerol



geraniol



ocimene

Table 1

## SUBSTITUTE SHEET (RULE 26)










(-)-*trans*-Caryophyllene

Table 2

## SUBSTITUTE SHEET (RULE 26)

Table 3. HYDROPATHY SCALE FOR AMINO ACID  
SIDE CHAINS

Side Chain	Hydropathy
Ile	4.5
Val	4.2
Leu	3.8
Phe	2.8
Cys	2.5
Met	1.9
Ala	1.8
Gly	-0.4
Thr	-0.7
Ser	-0.8
Trp	-0.9
Tyr	-1.3
Pro	-1.6
His	-3.2
Glu	-3.5
Gln	-3.5
Asp	-3.5
Asn	-3.5
Lys	-3.9
Arg	-4.5

- 44 -

Table 4: P450<sub>cam</sub> mutants

All mutants optionally contain the base mutation C334A.

Single mutants: Y96A, Y96F, Y96L, Y96W.

Double mutants:

Y96A-F87A	Y96F-F87A	Y96F-V295A	Y96L-F87A	Y96L-A296L
Y96A-F87L	Y96F-F87I	Y96F-V295L	Y96L-F87L	Y96L-A296F
Y96A-F87W	Y96F-F87L	Y96F-V295I	Y96L-F98W	Y96L-V396A
Y96A-F98W	Y96F-F87W	Y96F-A296L	Y96L-T101L	Y96L-V396L
Y96A-L244A	Y96F-F98W	Y96F-A296F	Y96L-T101F	Y96L-V396F
Y96A-V247A	Y96F-T101L	Y96F-I395F	Y96L-L244A	Y96L-V396W
Y96A-V247L	Y96F-T101F	Y96F-I395G	Y96L-L244F	
Y96A-I395F	Y96F-T185A	Y96F-V396A	Y96L-V247A	
Y96A-I395G	Y96F-T185F	Y96F-V396L	Y96L-V247L	Y96W-F87W
	Y96F-T185L	Y96F-V396F	Y96L-V247F	Y96W-F98W
	Y96F-L244A	Y96F-V396W	Y96L-V247W	Y96W-L244A
	Y96F-V247A		Y96L-G248L	Y96W-V247A
	Y96F-V247L		Y96L-V295L	Y96W-V396A
	Y96F-G248L		Y96L-V295F	

Triple Mutants:

Y96A-F87A-L244A	Y96L-V247A-V396L	Y96F-F87W-V247A
Y96A-F87A-V247A	Y96L-V247A-V396F	Y96F-F87W-V247L
Y96A-F87L-L244A	Y96L-V247A-V396W	Y96F-F87W-V247F
Y96A-F87L-V247A	Y96L-V247F-V396A	Y96F-F87W-V295L
Y96A-L244A-V247A		Y96F-F87W-A296L
	Y96F-F87A-L244A	Y96F-F87W-V396A
Y96L-F87A-L244A	Y96F-F87A-V247A	Y96F-F87W-V396L
Y96L-F87A-V247A	Y96F-F87A-V247L	Y96F-V247F-V396A
Y96L-F87L-L244A	Y96F-F87A-I395F	Y96F-L244A-V396L
Y96L-F87L-V247A	Y96F-F87A-I395G	Y96F-L244A-V396F
Y96L-V247A-I395F	Y96F-F87L-V247A	Y96F-L244A-V396W
Y96L-V247L-I395F	Y96F-F87L-V247L	Y96F-L244F-V396A
Y96L-V247L-I395G	Y96F-F87L-I395F	Y96F-V247A-V396L
Y96L-L244A-V396L	Y96F-F87W-T185A	Y96F-V247A-V396F
Y96L-L244A-V396F	Y96F-F87W-T185F	Y96F-V247A-V396W
Y96L-L244A-V396W	Y96F-F87W-T185L	
Y96L-L244F-V396A	Y96F-F87W-L244F	Y96W-F87W-F98W

Table 4 (continued)Four mutations:

Y96A-F87A-L244A-V247A  
Y96A-F87L-L244A-V247A  
Y96L-F87A-L244A-V247A  
Y96L-F87L-L244A-V247A

Five mutations:

Y96F-F87W-T185L-V247L-V295L  
Y96F-F87W-T185L-V247L-V396A  
Y96F-F87W-T185L-V247L-V396L

Y96F-F87W-L244A-V295L  
Y96F-F87W-L244F-V396A  
Y96F-F87W-L244A-A296L  
Y96F-F87W-V247A-V396L  
Y96F-F87W-V247A-V396F  
Y96F-F87W-V247L-V295A  
Y96F-F87W-V247L-V396A  
Y96F-F87W-V247F-V396A  
Y96F-F87W-V247A-I395F  
Y96F-F87W-V247L-I395G

**Table 5: P450<sub>BM-3</sub> mutants**

R47L-Y51F	R47L-Y51F-F42A	R47L-Y51F-F87A	R47L-Y51F-A264V
R47A-Y51A	R47L-Y51F-F42L	R47L-Y51F-F87W	R47L-Y51F-A264L
R47A-Y51L	R47A-Y51L-F42L	R47L-Y51F-I263A	R47L-Y51F-A264I
		R47L-Y51F-I263F	R47L-Y51F-M354L
		R47L-Y51F-I263L	R47L-Y51F-M354A
		R47L-Y51F-I263W	
			R47L-Y51F-L181A
			R47L-Y51F-L181W
			R47L-Y51F-F87W-A264L
			R47L-Y51F-F87W-A264I
			R47L-Y51F-F87W-A264F

**Table 6:** Summary of changes in selectivity of terpene oxidation by P450<sub>cam</sub> mutants. Approximate proportions of only the products arising from the insertion of a single oxygen atom, i.e., alcohols and epoxides, are given.

Mutant	Products, some also indicated by their retention times (min) on a 30 m DB-1 fused silica GC column					Comments
<b>L-Limonene</b>	5.23-5.33 min 1,2-Oxide	6.10-6.20 min Product	6.60 - 6.70 min Isopiperitenol	7.05-7.15 min Carveol	8.15-8.25 min Product	
Wild-type	-	30%	70%	-	-	Very small quantities
F87I-Y96F	8%	5%	5%	2%	80%	
Y96F-V247L	5%	-	>85%	5%	<5%	Other small peaks observed
Y96F-T185L	5%	<2%	>90%	<2%	<2%	Other small peaks observed
F87W-Y96F-V247L	<2%	-	>95%	<2%	-	
F87L-Y96F-V247L	5%	5%	5%	2%	>80%	
 <b>α-Pinene</b>						
Wild-type	Pinene oxide	Verbenol	Verbenone			
Y96F-V247A	10%	30%	10%			Remaining 50% other products
Y96F	10%	50%	20%			Remaining 20% other products
F87W-Y96F-V247L	10%	30%	15%			Many other products
	-	70%	15%			Very few other products
 <b>Valencene</b>						
Wild-type	Nookatol region	Nookatone	Product	Product	Product	
Y96F-V247A	9.60-9.70 min	9.80-9.90 min	11.3-11.4 min	13.0-13.1 min	14.0-14.1 min	
Y96L-V247A	-	-	-	-	-	Many small peaks
 <b>γ-Terpinene</b>						
Y96F	5.70-5.80 min	6.20-6.30 min				
	15%	85%				

- 48 -

Table 7: P450cam wild-type sequence

acg act gaa acc ata caa agc aac gcc aat ctt gcc cct ctg cca ccc	48
Thr Thr Glu Thr Ile Gln Ser Asn Ala Asn Leu Ala Pro Leu Pro Pro	
1 5 10 15	
cat gtg cca gag cac ctg gta ttc gac ttc gac atg tac aat ccg tcg	96
His Val Pro Glu His Leu Val Phe Asp Phe Asp Met Tyr Asn Pro Ser	
20 25 30	
aat ctg tct gcc ggc gtg cag gag gcc tgg gca gtt ctg caa gaa tca	144
Asn Leu Ser Ala Gly Val Gln Glu Ala Trp Ala Val Leu Gln Glu Ser	
35 40 45	
aac gta ccg gat ctg gtg tgg act cgc tgc aac ggc gga cac tgg atc	192
Asn Val Pro Asp Leu Val Trp Thr Arg Cys Asn Gly Gly His Trp Ile	
50 55 60	
gcc act cgc ggc caa ctg atc cgt gag gcc tat gaa gat tac cgc cac	240
Ala Thr Arg Gly Gln Leu Ile Arg Glu Ala Tyr Glu Asp Tyr Arg His	
65 70 75 80	
ttt tcc agc gag tgc ccg ttc atc cct cgt gaa gcc ggc gaa gcc tac	288
Phe Ser Ser Glu Cys Pro Phe Ile Pro Arg Glu Ala Gly Glu Ala Tyr	
85 90 95	
gac ttc att ccc acc tcg atg gat ccg ccc gag cag cgc cag ttt cgt	336
Asp Phe Ile Pro Thr Ser Met Asp Pro Pro Glu Gln Arg Gln Phe Arg	
100 105 110	
gcg ctg gcc aac caa gtg gtt ggc atg ccg gtg gtg gat aag ctg gag	384
Ala Leu Ala Asn Gln Val Val Gly Met Pro Val Val Asp Lys Leu Glu	
115 120 125	
aac cgg atc cag gag ctg gcc tgc tcg ctg atc gag agc ctg cgc ccg	432
Asn Arg Ile Gln Glu Leu Ala Cys Ser Leu Ile Glu Ser Leu Arg Pro	
130 135 140	
caa gga cag tgc aac ttc acc gag gac tac gcc gaa ccc ttc ccg ata	480
Gln Gly Gln Cys Asn Phe Thr Glu Asp Tyr Ala Glu Pro Phe Pro Ile	
145 150 155 160	

- 49 -

cgc atc ttc atg ctg ctc gca ggt cta ccg gaa gaa gat atc ccg cac 528  
 Arg Ile Phe Met Leu Leu Ala Gly Leu Pro Glu Glu Asp Ile Pro His  
 165 170 175  
  
 ttg aaa tac cta acg gat cag atg acc cgt ccg gat ggc agc atg acc 576  
 Leu Lys Tyr Leu Thr Asp Gln Met Thr Arg Pro Asp Gly Ser Met Thr  
 180 185 190  
  
 ttc gca gag gcc aag gag gcg ctc tac gac tat ctg ata ccg atc atc 624  
 Phe Ala Glu Ala Lys Glu Ala Leu Tyr Asp Tyr Leu Ile Pro Ile Ile  
 195 200 205  
  
 gag caa cgc agg cag aag ccg gga acc gac gct atc agc atc gtt gcc 672  
 Glu Gln Arg Arg Gln Lys Pro Gly Thr Asp Ala Ile Ser Ile Val Ala  
 210 215 220  
  
 aac ggc cag gtc aat ggg cga ccg atc acc agt gac gaa gcc aag agg 720  
 Asn Gly Gln Val Asn Gly Arg Pro Ile Thr Ser Asp Glu Ala Lys Arg  
 225 230 235 240  
  
 atg tgt ggc ctg tta ctg gtc ggc ggc ctg gat acg gtg gtc aat ttc 768  
 Met Cys Gly Leu Leu Val Gly Gly Leu Asp Thr Val Val Asn Phe  
 245 250 255  
  
 ctc agc ttc agc atg gag ttc ctg gcc aaa agc ccg gag cat cgc cag 816  
 Leu Ser Phe Ser Met Glu Phe Leu Ala Lys Ser Pro Glu His Arg Gln  
 260 265 270  
  
 gag ctg atc gag cgt ccc gag cgt att cca gcc gct tgc gag gaa cta 864  
 Glu Leu Ile Glu Arg Pro Glu Arg Ile Pro Ala Ala Cys Glu Glu Leu  
 275 280 285  
  
 ctc cgg cgc ttc tcg ctg gtt gcc gat ggc cgc atc ctc acc tcc gat 912  
 Leu Arg Arg Phe Ser Leu Val Ala Asp Gly Arg Ile Leu Thr Ser Asp  
 290 295 300  
  
 tac gag ttt cat ggc gtg caa ctg aag aaa ggt gac cag atc ctg cta 960  
 Tyr Glu Phe His Gly Val Gln Leu Lys Lys Gly Asp Gln Ile Leu Leu  
 305 310 315 320

- 50 -

ccg cag atg ctg tct ggc ctg gat gag cgc gaa aac gcc tgc ccg atg 1008

Pro Gln Met Leu Ser Gly Leu Asp Glu Arg Glu Asn Ala Cys Pro Met

325

330

335

cac gtc gac ttc agt cgc caa aag gtt tca cac acc acc ttt ggc cac 1056

His Val Asp Phe Ser Arg Glu Lys Val Ser His Thr Thr Phe Gly His

340

345

350

ggc agc cat ctg tgc ctt ggc cag cac ctg gcc cgc cgaa atc atc 1104

Gly Ser His Leu Cys Leu Gly Gln His Leu Ala Arg Arg Glu Ile Ile

355

360

365

gtc acc ctc aag gaa tgg ctg acc agg att cct gac ttc tcc att gcc 1152

Val Thr Leu Lys Glu Trp Leu Thr Arg Ile Pro Asp Phe Ser Ile Ala

370

375

380

ccg ggt gcc cag att cag cac aag agc ggc atc gtc agc ggc gtg cag 1200

Pro Gly Ala Gln Ile Gln His Lys Ser Gly Ile Val Ser Gly Val Gln

385

390

395

400

gca ctc cct ctg gtc tgg gat ccg gcg act acc aaa gcg gta 1242

Ala Leu Pro Leu Val Trp Asp Pro Ala Thr Thr Lys Ala Val

405

410

414

Table 8: P450<sub>BM-3</sub> sequence

1	/	1	31	/	11															
atg	aca	att	aaa	gaa	atg	cct	cag	cca	aaa	acg	ttt	gga	gag	ctt	aaa	aat	tta	ccg	tta	
Met	Thr	Ile	Lys	Glu	Met	Pro	Gln	Pro	Lys	Thr	Phe	Gly	Glu	Leu	Lys	Asn	Leu	Pro	Leu	
61	/	21								91	/	31								
tta	aac	aca	gat	aaa	ccg	gtt	caa	gct	ttg	atg	aaa	att	gcg	gat	gaa	tta	gga	gaa	atc	
Leu	Asn	Thr	Asp	Lys	Pro	Val	Gln	Ala	Leu	Met	Lys	Ile	Ala	Asp	Glu	Leu	Gly	Glu	Ile	
121	/	41								151	/	51								
ttt	aaa	tcc	gag	gcg	cct	ggt	cgt	gta	acg	cgc	tac	tta	tca	agt	cag	cgt	cta	att	aaa	
Phe	Lys	Phe	Glu	Ala	Pro	Gly	Arg	Val	Thr	Tyr	Leu	Ser	Ser	Gln	Arg	Leu	Ile	Lys		
181	/	61								211	/	71								
gaa	gca	tgc	gat	gaa	tca	cgc	ttt	gat	aaa	aac	tta	agt	caa	gcg	ctt	aaa	ttt	gta	cgt	
Glu	Ala	Cys	Asp	Glu	Ser	Arg	Phe	Asp	Lys	Asn	Leu	Ser	Gln	Ala	Leu	Lys	Phe	Val	Arg	
241	/	81								271	/	91								
gat	ttt	gca	gga	gac	ggg	tta	ttt	aca	agc	tgg	acg	cat	gaa	aaa	aat	tgg	aaa	aaa	gcg	
Asp	Phe	Ala	Gly	Asp	Gly	Leu	Phe	Thr	Ser	Trp	Thr	His	Glu	Lys	Asn	Trp	Lys	Lys	Ala	
301	/	101								331	/	111								
cat	aat	atc	tta	ctt	cca	agc	ttc	agt	cag	gca	atg	aaa	ggc	tat	cat	gcg	atg	atg		
His	Asn	Ile	Leu	Leu	Pro	Ser	Phe	Ser	Gln	Gln	Ala	Met	Lys	Gly	Tyr	His	Ala	Met	Met	
361	/	121								391	/	131								
gtc	gat	atc	gcc	gtg	cag	ctt	gtt	caa	aag	tgg	gag	cgt	cta	aat	gca	gat	gag	cat	att	
Val	Asp	Ile	Ala	Val	Gln	Leu	Val	Gln	Lys	Trp	Glu	Arg	Leu	Asn	Ala	Asp	Glu	His	Ile	
421	/	141								451	/	151								
gaa	gta	ccg	gaa	gac	atg	aca	cgt	tta	acg	ctt	gat	aca	att	ggt	ctt	tgc	ggc	ttt	aac	
Glu	Val	Pro	Glu	Asp	Met	Thr	Arg	Leu	Thr	Leu	Asp	Thr	Ile	Gly	Leu	Cys	Gly	Phe	Asn	
481	/	161								511	/	171								
tat	cgc	ttt	aac	agc	ttt	tac	cga	gat	cag	cct	cat	cca	ttt	att	aca	agt	atg	gtc	cgt	
Tyr	Arg	Phe	Asn	Ser	Phe	Tyr	Arg	Asp	Gln	Pro	Phe	Ile	Thr	Ser	Met	Val	Arg			
541	/	181								571	/	191								
gca	ctg	gat	gaa	gca	atg	aac	aag	ctg	cag	cga	gca	aat	cca	gac	gac	cca	gct	tat	gat	
Ala	Leu	Asp	Glu	Ala	Met	Asn	Lys	Leu	Gln	Arg	Ala	Asn	Pro	Asp	Asp	Pro	Ala	Tyr	Asp	
601	/	201								631	/	211								
gaa	aac	aag	cgc	cag	ttt	caa	gaa	gat	atc	aag	gtg	atg	aac	gac	cta	gta	gat	aaa	att	
Glu	Asn	Lys	Arg	Gln	Phe	Gln	Glu	Asp	Ile	Lys	Val	Met	Asn	Asp	Leu	Val	Asp	Lys	Ile	
661	/	221								691	/	231								
att	gca	gat	cgc	aaa	gca	agc	ggt	gaa	caa	agc	gat	gat	tta	tta	acg	cat	atg	cta	aac	
Ile	Ala	Asp	Arg	Lys	Ala	Ser	Gly	Glu	Gln	Ser	Asp	Asp	Leu	leu	Thr	His	Met	Leu	Asn	
721	/	241								751	/	251								
gga	aaa	gat	cca	gaa	acg	ggt	gag	ccg	ctt	gat	gac	gag	aac	att	cgc	tat	caa	att	att	
Gly	Lys	Asp	Pro	Glu	Thr	Gly	Glu	Pro	Leu	Asp	Asp	Glu	Asn	Ile	Arg	Tyr	Gln	Ile	Ile	
781	/	261								811	/	271								
aca	tcc	tta	att	gcg	gga	cac	gaa	aca	aca	agt	ggt	ctt	tca	ttt	gcg	ctg	tat	tcc		
Thr	Phe	Leu	Ile	Ala	Gly	His	Glu	Thr	Thr	Ser	Gly	Leu	Leu	Ser	Phe	Ala	leu	Tyr	Phe	
841	/	281								871	/	291								
ttt	gtg	aaa	aat	cca	cat	gta	tta	caa	aaa	gca	gca	gaa	gca	gca	cga	gtt	cta	gta		
Leu	Val	Lys	Asn	Pro	His	Val	Leu	Gln	Lys	Ala	Ala	Glu	Glu	Ala	Ala	Arg	Val	Leu	Val	
901	/	301								931	/	311								
gat	cct	gct	cca	agc	tac	aaa	caa	gtc	aaa	cag	ctt	aaa	tat	gtc	ggc	atg	gtc	tta	aac	
Asp	Pro	Val	Pro	Ser	Tyr	Lys	Gln	Val	Lys	Gln	Leu	Lys	Tyr	Val	Gly	Met	Val	Leu	Asn	
961	/	321								991	/	331								
gaa	ggc	ctg	cgc	tta	tgg	cca	act	gct	cct	gcg	ttt	tcc	cta	tat	gca	aaa	gaa	gat	acg	
Glu	Ala	Leu	Arg	Leu	Trp	Pro	Thr	Ala	Pro	Ala	Phe	Ser	Leu	Tyr	Ala	Lys	Glu	Asp	Thr	
1021	/	341								1051	/	351								
gtg	ctt	ggg	gga	gaa	tat	cct	tta	gaa	aaa	ggc	gac	gaa	cta	atg	gtt	ctg	att	cct	cag	
Val	Leu	Gly	Gly	Glu	Tyr	Pro	Leu	Glu	Lys	Gly	Asp	Glu	Leu	Met	Val	Leu	Ile	Pro	Gln	
1081	/	361								1111	/	371								
ctt	cac	cgt	gat	aaa	aca	att	tgg	gga	gac	gat	gtg	gaa	gag	ttc	cgt	cca	gag	cgt	ttt	
Leu	His	Arg	Asp	Lys	Thr	Ile	Trp	Gly	Asp	Asp	Val	Glu	Phe	Arg	Pro	Glu	Arg	Phe		
1141	/	381								1171	/	391								
gaa	aat	cca	agt	gcg	att	ccg	cag	cat	gcg	ttt	aaa	ccg	ttt	gga	aac	ggt	cag	cgt	gct	
Glu	Asn	Pro	Ser	Ala	Ile	Pro	Gln	His	Ala	Phe	Lys	Pro	Phe	Gly	Asn	Gly	Gln	Arg	Ala	
1201	/	401								1231	/	411								
tgt	atc	ggc	cag	cag	ttc	gct	ctt	cat	gaa	gca	acg	ctg	gta	ctt	ggc	atg	atg	cta	aaa	
Cys	Ile	Gly	Gln	Gln	Phe	Ala	Leu	His	Glu	Ala	Thr	Leu	Val	Leu	Gly	Met	Met	Leu	Lys	
1261	/	421								1291	/	431								
cac	ttt	gac	ttt	gaa	gat	cat	aca	aac	tac	gag	ctg	gat	att	aaa	gaa	act	tta	acg	tta	
His	Phe	Asp	Phe	Glu	Asp	His	Thr	Asn	Tyr	Glu	Leu	Asp	Ile	Lys	Glu	Thr	Leu	Thr	Leu	
1321	/	441								1351	/	451								
aaa	cct	gaa	ggc	ttt	gtg	gta	aaa	gca	aaa	tcc	aaa	aaa	att	ccg	ttt	ggc	ggt	att	cct	
Lys	Pro	Glu	Gly	Phe	Val	Val	Lys	Ala	Lys	Ser	Lys	Lys	Ile	Pro	Leu	Gly	Gly	Ile	Pro	
1381	/	461								1411	/	471								

- 53 -

cat gaa gac tat ctg tat caa gaa gag ctt gaa aac gcc caa agc gaa ggc atc att acg  
His Glu Asp Tyr Leu Tyr Gln Glu Glu Leu Glu Asn Ala Gln Ser Glu Gly Ile Ile Thr  
2881 / 961 2911 / 971  
ctt cat acc gct ttt tct cgc atg cca aat cag ccg aaa aca tac gtt cag cac gta atg  
Leu His Thr Ala Phe Ser Arg Met Pro Asn Gln Pro Lys Thr Tyr Val Gln His Val Met  
2941 / 981 2971 / 991  
gaa caa gac ggc aag aaa ttg att gaa ctt ctt gat caa gga gcg cac ttc tat att tgc  
Glu Gln Asp Gly Lys Lys Leu Ile Glu Leu Leu Asp Gln Gly Ala His Phe Tyr Ile Cys  
3001 / 1001 3031 / 1011  
gga gac gga agc caa atg gca cct gcc gtt gaa gca acg ctt atg aaa agc tat gct gac  
Gly Asp Gly Ser Gln Met Ala Pro Ala Val Glu Ala Thr Leu Met Lys Ser Tyr Ala Asp  
3061 / 1021 3091 / 1031  
gtt cac caa gtg agt gaa gca gac gct cgc tta tgg ctg cag cag cta gaa gaa aaa ggc  
Val His Gln Val Ser Glu Ala Asp Ala Arg Leu Trp Leu Gln Gln Leu Glu Glu Lys Gly  
3121 / 1041  
cga tac gca aaa gac gtg tgg gct ggg taa  
Arg Tyr Ala Lys Asp Val Trp Ala Gly OCH

tca cct agc act gaa cag tct gcc aaa aaa gca cgc aaa aag gca gaa aac gct cat aat  
 Ser Pro Ser Thr Glu Gln Ser Ala Lys Lys Val Arg Lys Lys Ala Glu Asn Ala His Asn  
 1441 / 481 1471 / 491  
 acg ccg ctg ctt gtg cta tac ggt tca aat atg gga aca gct gaa gga acg gcg cgt gat  
 Thr Pro Leu Leu Val Leu Tyr Gly Ser Asn Met Gly Thr Ala Glu Gly Thr Ala Arg Asp  
 1501 / 501 1531 / 511  
 tta gca gat att gca atg agc aaa gga ttt gca ccg cag gtc gca acg ctt gat tca cac  
 Leu Ala Asp Ile Ala Met Ser Lys Gly Phe Ala Pro Gln Val Ala Thr Leu Asp Ser His  
 1561 / 521 1591 / 531  
 gcc gga aat ctt ccg cgc gaa gga gct gta tta att gta acg gcg tct tat aac ggt cat  
 Ala Gly Asn Leu Pro Arg Glu Gly Ala Val Leu Ile Val Thr Ala Ser Tyr Asn Gly His  
 1621 / 541 1651 / 551  
 ccg cct gat aac gca aag caa ttt gtc gac tgg tta gac caa gcg tct gct gat gaa gta  
 Pro Pro Asp Asn Ala Lys Gln Phe Val Asp Trp Leu Asp Gln Ala Ser Ala Asp Glu Val  
 1681 / 561 1711 / 571  
 aaa ggc gtt ccg tac tcc gta ttt gga tgc ggc gat aaa aac tgg gct act acg tat caa  
 Lys Gly Val Arg Tyr Ser Val Phe Gly Cys Gly Asp Lys Asn Trp Ala Thr Thr Tyr Gln  
 1741 / 581 1771 / 591  
 aaa gtg cct gct ttt atc gat gaa acg ctt gcc gct aaa ggg gca gaa aac atc gct gac  
 Lys Val Pro Ala Phe Ile Asp Glu Thr Leu Ala Ala Lys Gly Ala Glu Asn Ile Ala Asp  
 1801 / 601 1831 / 611  
 cgc ggt gaa gca gat gca agc gac gac ttt gaa ggc aca tat gaa gaa tgg cgt gaa cat  
 Arg Gly Glu Ala Asp Ala Ser Asp Asp Phe Glu Gly Thr Glu Glu Trp Arg Glu His  
 1861 / 621 1891 / 631  
 atg tgg agt gac gta gca gcc tac ttt aac ctc gac att gaa aac agt gaa gat aat aaa  
 Met Trp Ser Asp Val Ala Ala Tyr Phe Asn Leu Asp Ile Glu Asn Ser Glu Asp Asn Lys  
 1921 / 641 1951 / 651  
 tct act ctt tca ctt caa ttt gtc gac agc gcc gcg gat atg ccc ctt gcg aaa atg cac  
 Ser Thr Leu Ser Leu Gln Phe Val Asp Ser Ala Ala Asp Met Pro Leu Ala Lys Met His  
 1981 / 661 2011 / 671  
 ggt ggc ttt tca acg aac gtc gta gca agc aaa gaa ctt caa cag cca ggc agt gca cga  
 Gly Ala Phe Ser Thr Asn Val Val Ala Ser Lys Glu Leu Gln Gln Pro Gly Ser Ala Arg  
 2041 / 681 2071 / 691  
 agc acg cga cat ctt gaa att gaa ctt cca aaa gaa gct tct tat caa gaa gga gat cat  
 Ser Thr Arg His Leu Glu Ile Glu Leu Pro Lys Glu Ala Ser Tyr Gln Glu Gly Asp His  
 2101 / 701 2131 / 711  
 tta ggt gtt att cct ccg aac tat gaa gga ata gta aac cgt gta aca gca agg ttc ggc  
 Leu Gly Val Ile Pro Arg Asn Tyr Glu Gly Ile Val Asn Arg Val Thr Ala Arg Phe Gly  
 2161 / 721 2191 / 731  
 cta gat gca tca cag caa atc cgt ctg gaa gca gaa gaa aaa tta gct cat ttg cca  
 Leu Asp Ala Ser Gln Gln Ile Arg Leu Glu Ala Glu Glu Glu Lys Leu Ala His Leu Pro  
 2221 / 741 2251 / 751  
 ctc gct aaa aca gta tcc gta gaa gag ctt ctg cca tac gtg gag ctt caa gat cct gtt  
 Leu Ala Lys Thr Val Ser Val Glu Glu Leu Leu Gln Tyr Val Glu Leu Gln Asp Pro Val  
 2281 / 761 2311 / 771  
 acg cgc acg cag ctt ccg gca atg gct gct aaa acg gtc tgc ccc ccc cat aaa gta gag  
 Thr Arg Thr Gln Leu Arg Ala Met Ala Ala Lys Thr Val Cys Pro Pro His Lys Val Glu  
 2341 / 781 2371 / 791  
 ctt gaa gcc ttg ctt gaa aag caa gcc tac aaa gaa caa gtg ctg gca aaa cgt tta aca  
 Leu Glu Ala Leu Leu Glu Lys Gln Ala Tyr Lys Glu Gln Val Leu Ala Lys Arg Leu Thr  
 2401 / 801 2431 / 811  
 atg ctt gaa ctg ctt gaa aaa tac ccg ggc tgt gaa atg aaa ttc agc gaa ttt atc gcc  
 Met Leu Glu Leu Leu Lys Tyr Pro Ala Cys Glu Met Lys Phe Ser Glu Phe Ile Ala  
 2461 / 821 2491 / 831  
 ctt ctg cca agc ata cgc ccg cgc tat tac tcg att tct tca tca cct cgt gtc gat gaa  
 Leu Leu Pro Ser Ile Arg Pro Arg Tyr Tyr Ser Ile Ser Ser Ser Pro Arg Val Asp Glu  
 2521 / 841 2551 / 851  
 aaa caa gca agc atc acg gtc agc gtt gtc tca gga gaa gcg tgg agc gga tat gga gaa  
 Lys Gln Ala Ser Ile Thr Val Ser Val Val Ser Gly Glu Ala Trp Ser Gly Tyr Gly Glu  
 2581 / 861 2611 / 871  
 tat aaa gga att gcg tcg aac tat ctt gcc gag ctg caa gaa gga gat acg att acg tgc  
 Tyr Lys Gly Ile Ala Ser Asn Tyr Leu Ala Glu Leu Gln Glu Gly Asp Thr Ile Thr Cys  
 2641 / 881 2671 / 891  
 ttt att tcc aca ccc cag tca gaa ttt acg ctg cca aaa gac cct gaa acg ccg ctt atc  
 Phe Ile Ser Thr Pro Gln Ser Glu Phe Thr Leu Pro Lys Asp Pro Glu Thr Pro Leu Ile  
 2701 / 901 2731 / 911  
 atg gtc gga ccg gga aca ggc gtc ggc ccg ttt aga ggc ttt gtg cag ggc cgc aaa cag  
 Met Val Gly Pro Gly Thr Gly Val Ala Pro Phe Arg Gly Phe Val Gln Ala Arg Lys Gln  
 2761 / 921 2791 / 931  
 cta aaa gaa caa gga cag tca ctt gga gaa gca cat tta tac ttc ggc tgc cgt tca cct  
 Leu Lys Glu Gln Gly Gln Ser Leu Gly Glu Ala His Leu Tyr Phe Gly Cys Arg Ser Pro  
 2821 / 941 2851 / 951

-54-

CLAIMS

1. Process for oxidising a substrate which is an acyclic or cyclic terpene, or a cycloalkene; or a substituted derivative thereof, which process comprises  
5 oxidising said compound with a mutant haem-containing enzyme, the mutant comprising the substitution of an amino acid in the active site by an amino acid with a less polar side-chain.

10 2. Process according to claim 1 in which the enzyme is a mutant of P450<sub>cam</sub> or P450<sub>BM-3</sub>, or a mutant of a naturally occurring homologue of either of these enzymes.

15 3. Process according to claim 2 in which the enzyme is one in which amino acid 47 and/or 51 of P450<sub>BM-3</sub>, or amino acid 96 of P450<sub>cam</sub>, or the equivalent amino acid(s) in a said homologue, have been changed to an amino acid with a less polar side-chain.

20 4. Process according to any one of claims 1, 2 or 3 in which there are one or more other amino acid substitutions in the active site.

25 5. Process according to any one of the preceding claims in which the enzyme is (i) P450<sub>cam</sub> and comprises one or more of the following mutations: F87W, F87I, F87L, T185L, T185F, V247A, V247L or F87A-I395F; or (ii) P450<sub>BM-3</sub> and comprises the mutation R47L-Y51F.

30 6. An enzyme as defined in claim 4 or 5 excluding mutants of P450<sub>cam</sub> which only have the mutations F87A-Y96G-F193A, F87A-Y96G-F193A-C334A, or T101M-T185F-V247M.

7. A polynucleotide which comprises a sequence which encodes an enzyme as defined in claim 6.

35 8. A cell which expresses:

(i) an enzyme as defined in any one of claims 2 to 6 which in its naturally occurring form has an electron transfer reductase domain, or

(ii) (a) an enzyme as defined in any one of claims 1 to

35 5;

-55-

- (b) an electron transfer reductase; and
- (c) an electron transfer redoxin.

9. A cell which expresses:

- (a) (i) P450<sub>cam</sub>, or a fragment thereof; or
- 5 (ii) a naturally occurring homologue of P450<sub>cam</sub> or a fragment thereof; or
- (iii) a mutant P450<sub>cam</sub>, or a mutant homologue of thereof

as defined in any one of claims 2 to 5; or

- 10 (iv) a P450<sub>cam</sub> which has at least 70% amino acid homology with (i), (ii) or (iii) and optionally has the mutations defined in any one of claims 3 to 5; and

- (b) an electron transfer reductase; and

- 15 (c) an electron transfer redoxin:

excluding an *E.Coli* DH5 $\alpha$  cell in which the only mutants of P450<sub>cam</sub> which are expressed are amongst the following:

20 H<sub>2</sub>N-P450<sub>cam</sub>-TDGTSST-putidaredoxin reductase-TDGASSS-putidaredoxin-COOH,

H<sub>2</sub>N-P450<sub>cam</sub>-TDGTRPGPGPGPGPSST-putidaredoxin reductase-TDGASSS-putidaredoxin-COOH,

H<sub>2</sub>N-P450<sub>cam</sub>-TDGTRPGPGPGPGPGPSST-putidaredoxin reductase-TDGASSS-putidaredoxin-COOH,

25 H<sub>2</sub>N-putidaredoxin reductase-TDGASSS-putidaredoxin-PLEL-P450<sub>cam</sub>-COOH.

10. A cell according to claim 8 or 9 in which (a), (b) and (c) or (b) and (c) are expressed together in the same fusion protein.

30 11. A cell according to any one of claims 8 to 10 in which:

- (b) is putidaretoxin reductase or a fragment thereof; and/or
- (c) is putidaretoxin or a fragment thereof.

-56-

12. A cell which expresses:

(a) (i) P450<sub>BM-3</sub>, or a fragment thereof; or  
(ii) a naturally occurring homologue of P450<sub>BM-3</sub>,  
or a fragment thereof; or  
5 (iii) a mutant P450<sub>BM-3</sub>, or a mutant  
homologue of thereof  
as defined in any one of claims 2 to 5.

13. A process according to any one of claims 1 to 5  
in which the compound is oxidised in a cell according to  
10 any one of claims 8 to 12

14. A process for making a library of mutants of  
P450<sub>cam</sub> or P450<sub>BM-3</sub>, or mutants of a homologue of either of  
these enzymes comprising contacting a cell according to  
any one of claims 9, and 10 and 11 when dependent on  
15 claim 9, or according to claim 12 or an *E.Coli* DH5 $\alpha$  cell  
as defined in claim 9;

with a mutagen and/or when then the cell is a  
mutator cell culturing the cell in conditions in which  
mutants are produced.

20 15. Process for selecting a mutant of P450<sub>cam</sub> or  
P450<sub>BM-3</sub>, or a homologue thereof, for its ability to  
oxidise a particular substrate, which process comprises  
screening a group of said mutants for their oxidation  
effect on the particular substrate.

25 16. Process according to claim 15 in which the  
mutant is additionally selected for its ability to  
oxidise the particular compound to a particular oxidation  
product.

30 17. A process according to claim 15 or 16 in which  
the screening is carried out on the library made in a  
process according to claim 14.

35 18. A process for producing a library of oxidation  
products comprising providing a substrate as defined in  
claim 1 to a library made in a process according to claim  
14 and allowing oxidation of the substrate.

-57-

19. An oxidation product obtained by a process according to any one of claims 1 to 5 and 13 wherein optionally the enzyme is one which has been selected in a process according to claim 15, 16 or 17 for use in a  
5 method of treatment of the human or animal body by therapy.

10 20. A pharmaceutical composition comprising an oxidation product obtained by a process according to any one of claims 1 to 5 and 13 wherein optionally the enzyme is one which has been selected in a process according to claim 15, 16 or 17 and a pharmaceutically acceptable carrier or diluent.

Fig. 1.







Fig.2.



3/4

Fig.3.



**Fig.4.**



**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C12N 15/53, 9/02, 1/21, 15/01, C12P 7/02</b> // (C12N 9/02, C12R 1:40) (C12N 9/02, C12R 1:11) (C12N 1/21, C12R 1:19)		A3	(11) International Publication Number: <b>WO 00/31273</b> (43) International Publication Date: 2 June 2000 (02.06.00)		
(21) International Application Number: <b>PCT/GB99/03873</b>		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).			
(22) International Filing Date: 19 November 1999 (19.11.99)		(82) Published <i>With international search report.</i>			
(30) Priority Data: 9825421.2 19 November 1998 (19.11.98) GB		(88) Date of publication of the international search report: 17 August 2000 (17.08.00)			
(71) Applicant (for all designated States except US): ISIS INNOVATION LIMITED [GB/GB]; Ewert House, Ewert Place, Summertown, Oxford OX2 7BZ (GB).					
(72) Inventors; and					
(75) Inventors/Applicants (for US only): WONG, Luet, Lok [GB/GB]; University of Oxford, Dept. of Chemistry, South Parks Road, Oxford OX1 3QR (GB). BELL, Stephen, Graham [GB/GB]; University of Oxford, Dept. of Chemistry, South Parks Road, Oxford OX1 3QR (GB). CARMICHAEL, Angus, Bishop [GB/GB]; University of Oxford, Dept. of Chemistry, South Parks Road, Oxford OX1 3QR (GB).					
(74) Agent: ELLIS-JONES, Patrick, George, Armine; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5LX (GB).					
(54) Title: PROCESS FOR OXIDISING TERPENES					
(57) Abstract					
A process for oxidising a substrate which is an acyclic or cyclic terpene, or a cycloalkene; or a substituted derivative thereof, which process comprises oxidising said compound with a mutant haem-containing enzyme, the mutant comprising the substitution of an amino acid in the active site by an amino acid with a less polar side-chain. The enzyme is typically P450 <sub>cam</sub> or P450 <sub>BM-3</sub> . Cells and libraries of cells in which the process can be carried out or which can be used to select advantageous mutant enzymes are also provided.					

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## INTERNATIONAL SEARCH REPORT

Inte	Application No
PCT/GB 99/03873	

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/53 C12N9/02 C12N1/21 C12N15/01 C12P7/02  
 //((C12N9/02,C12R1:40),(C12N9/02,C12R1:11),(C12N1/21,  
 C12R1:19))

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 2 294 692 A (BRITISH GAS PLC) 8 May 1996 (1996-05-08)	1-6
Y	abstract table 1 table 2A table 4 --- -/-	8-11

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

28 February 2000

Date of mailing of the international search report

23.05.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Lejeune, R

## INTERNATIONAL SEARCH REPORT

PCT/GB 99/03873

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>ATKINS W M ET AL: "Molecular recognition in cytochrome P-450: alteration of regioselective alkane hydroxylation via protein engineering." JOURNAL OF THE AMERICAN CHEMICAL SOCIETY., vol. 111, 1989, pages 2715-2717, XP002131692 AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC., US ISSN: 0002-7863 the whole document</p> <p>---</p>	1-6
Y	<p>SIBBESEN O ET AL: "Putidaredoxin reductase-putidaredoxin-cytochrome P450cam triple fusion protein" JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 271, no. 37, 13 September 1996 (1996-09-13), pages 22462-22469, XP002131693 AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD., US ISSN: 0021-9258 abstract</p> <p>---</p>	8-11
A	<p>OLIVER C F ET AL: "A single mutation in cytochrome P450 BM3 changes substrate orientation in a catalytic intermediate and the regiospecificity of hydroxylation." BIOCHEMISTRY., vol. 36, 1997, pages 1567-1572, XP002131694 AMERICAN CHEMICAL SOCIETY. EASTON, PA., US ISSN: 0006-2960 abstract</p> <p>---</p>	1-5
X	<p>ENGLAND P A: "The oxidation of naphthalene and pyrene by cytochrome P450cam" FEBS LETTERS., vol. 424, 13 March 1998 (1998-03-13), pages 271-274, XP002131695 ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM., NL ISSN: 0014-5793 abstract</p> <p>---</p> <p>-/-</p>	1-6

## INTERNATIONAL SEARCH REPORT

Inter Application No  
PCT/GB 99/03873

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ATKINS W M ET AL: "THE ROLES OF ACTIVE SITE HYDROGEN BONDING IN CYTOCHROME P-450 CAM AS REVEALED BY SITE-DIRECTED MUTAGENESIS" JOURNAL OF BIOLOGICAL CHEMISTRY, US, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 263, no. 35, 15 December 1988 (1988-12-15), pages 18842-18849, XP002025958 ISSN: 0021-9258 abstract -----	1-6

# INTERNATIONAL SEARCH REPORT

national application No.

PCT/GB 99/03873

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheets

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-14, 17-20 all partially

### Remark on Protest

The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

**1. Claims: 1-14,17-20 all partially**

A mutant P-450 cam in which amino acid 96 has been changed to an amino acid with a less polar side-chain. Also a nucleotide encoding it, a process for oxidising a terpene or a cycloalkene with it, a cell expressing it.

**2. Claims: 1-14,17-20 all partially**

Same as invention 1, but pertaining to a mutant P-450 cam in which amino acid 87 has been changed.

**3. Claims: 1-14,17-20 all partially**

Same as invention 1, but pertaining to a mutant P-450 cam in which amino acid 185 has been changed.

**4. Claims: 1-14,17-20 all partially**

Same as invention 1, but pertaining to a mutant P-450 cam in which amino acid 247 has been changed.

**5. Claims: 1-14,17-20 all partially**

Same as invention 1, but pertaining to a mutant P-450 cam in which an amino acid in the active site has been changed to an amino acid with a less polar side-chain, as far as not covered by (1)-(4).

**6. Claims: 1-8,10,12-14,17-20 all partially**

Same as invention 1, but pertaining to a mutant P-450 BM3 in which amino acid 47 has been changed.

**7. Claims: 1-8,10,12-14,17-20 all partially**

Same as invention 1, but pertaining to a mutant P-450 BM3 in which amino acid 51 has been changed.

**8. Claims: 1-8,10,12-14,17-20 all partially**

Same as invention 1, but pertaining to a mutant P-450 BM3 in which amino acid in the active site has been changed to an amino acid with a less polar side-chain, as far as not covered by (6)-(7).

**9. Claims: 8-11,13,14,17-20 all partially**

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A cell which expresses P-450 cam, or a fragment thereof or a naturally occurring homologue or a mutant thereof, and an electron transfer reductase and an electron transfer redoxin.

10. Claims: 8,10-14,17-20 all partially

A cell which expresses P-450 BM-3, or a fragment thereof or a naturally occurring homologue or a mutant thereof.

11. Claims: 14,17-20 all partially

A process for making a library of mutants of P-450 cam or P-450 BM3 by treating cells expressing P-450 cam or P-450 BM3 with a mutagen or when the cells are mutator cells, culturing them in conditions in which mutants are produced.

12. Claims: 15,16 all completely, 17,19,20 all partially

A process for selecting a mutant of P-450 cam or P-450 BM3 for its ability to oxidise a particular substance, comprising screening a group of mutants for their oxidation effect on the particular substance.

**INTERNATIONAL SEARCH REPORT**

main patent family members

Inter Application No  
PCT/GB 99/03873

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
GB 2294692	A 08-05-1996	AU	705736 B	03-06-1999
		AU	3811795 A	31-05-1996
		CN	1171818 A	28-01-1998
		CZ	9701277 A	15-10-1997
		EP	0789770 A	20-08-1997
		WO	9614419 A	17-05-1996
		JP	10503658 T	07-04-1998
		NZ	294904 A	24-09-1998
		PL	319970 A	01-09-1997
		SK	54597 A	04-02-1998

**THIS PAGE BLANK (USPTO)**